

23 ⁶Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of
24 Medicine at Mount Sinai, New York, New York, USA

25 ⁷Department of Electrical and Computer Engineering, KLESSE School of Engineering
26 and Integrated Design, University of Texas at San Antonio, San Antonio, TX, USA

27 ⁸Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh
28 School of Medicine, Pittsburgh, PA, USA

29

30 †These authors contributed equally to this work.

31 *Corresponding authors. Emails: yuh119@pitt.edu; gaos8@upmc.edu

32 **Abstract**

33 Despite intensive studies during the last 3 years, the pathology and underlying
34 molecular mechanism of coronavirus disease 2019 (COVID-19) remain poorly defined.
35 Here, we examined postmortem COVID-19 lung tissues by spatial single-cell
36 transcriptome analysis (SSCTA). We identified 18 major parenchymal and immune cell
37 types, all of which are infected by SARS-CoV-2. Compared to the non-COVID-19
38 control, COVID-19 lungs have reduced alveolar cells (ACs), and increased innate and
39 adaptive immune cells. Additionally, 19 differentially expressed genes in both infected
40 and uninfected cells across the tissues mirror the altered cellular compositions. Spatial
41 analysis of local infection rates revealed regions with high infection rates that are
42 correlated with high cell densities (HIHD). The HIHD regions express high levels of
43 SARS-CoV-2 entry-related factors including ACE2, FURIN, TMPRSS2, and NRP1, and
44 co-localized with organizing pneumonia (OP) and lymphocytic and immune infiltration
45 that have increased ACs and fibroblasts but decreased vascular endothelial cells and
46 epithelial cells, echoing the tissue damage and wound healing processes. Sparse non-
47 negative matrix factorization (SNMF) analysis of neighborhood cell type composition
48 (NCTC) features identified 7 signatures that capture structure and immune niches in
49 COVID-19 tissues. Trajectory inference based on immune niche signatures defined two
50 pathological routes. Trajectory A progresses with primarily increased NK cells and
51 granulocytes, likely reflecting the complication of microbial infections. Trajectory B is
52 marked by increased HIHD and OP, possibly accounting for the increased immune
53 infiltration. The OP regions are marked by high numbers of fibroblasts expressing
54 extremely high levels of COL1A1 and COL1A2. Examination of single-cell RNA-seq

55 data (scRNA-seq) from COVID-19 lung tissues and idiopathic pulmonary fibrosis (IPF)
56 identified similar cell populations primarily consisting of myofibroblasts.
57 Immunofluorescence staining revealed the activation of IL6-STAT3 and TGF- β -
58 SMAD2/3 pathways in these cells, which likely mediate the upregulation of COL1A1 and
59 COL1A2, and excessive fibrosis in the lung tissues. Together, this study provides an
60 SSCTA atlas of cellular and molecular signatures of fatal COVID-19 lungs, revealing the
61 complex spatial cellular heterogeneity, organization, and interactions that characterized
62 the COVID-19 lung pathology.

63

64 **Key words:** SSCTA, spatial single-cell transcriptome analysis; COVID-19, coronavirus
65 disease 2019; SARS-CoV-2; SNMF, sparse non-negative matrix factorization analysis;
66 NCTC, neighborhood cell type composition analysis; trajectory inference; organizing
67 pneumonia; fibrosis; IL6-STAT3; TGF- β -SMAD2/3

68 **Introduction**

69 Multiple single-cell RNA-seq (scRNA-seq) analyses of coronavirus disease 2019
70 (COVID-19) patients with different severities have improved our understanding of
71 cellular diversity associated with infection and provided important molecular insights into
72 the host immune response [1-5]. Despite intensive studies in the last 3 years, the
73 pathology and underlying molecular mechanism of COVID-19 remain unclear. Severe
74 COVID-19 is often accompanied by diffuse alveolar damage (DAD) that presents
75 complex pathological manifestations and is heterogeneous within infected tissues and
76 across patients [6]. The dissociation of tissue localization of cells in scRNA-seq has
77 become a bottleneck to decoding the pathology features at the molecular and cellular
78 levels and failed to reveal the immune signatures of the microenvironment for severe
79 COVID-19.

80 Spatial single-cell transcriptome analysis (SSCTA) promises to reveal the
81 molecular basis of cellular heterogeneity, organization, and interactions in tissues and
82 organs [7, 8]. However, analysis of these complex datasets including defining the spatial
83 cellular organizations, immune microenvironment patterns, cell-cell interactions, and
84 molecular signatures associated with disease pathophysiology remains a daunting task.

85 Here, we utilized SSCTA to examine postmortem lung tissues from 5 cases with
86 severe COVID-19 and one case without COVID-19. From 10,414,863 detected
87 transcripts of cellular 221 genes from six tissues, we identified 1,719,459 cells that were
88 mapped to 18 major parenchymal and immune cell types, all of which are infected by
89 SARS-CoV-2. We further identified the spatial cellular and molecular signatures that
90 define the patterns of SARS-CoV-2 infection, structural and pathological presentations,

91 and associated immune microenvironments, which project the trajectories of disease
92 progression. Together, this study provides an atlas of cellular and molecular signatures
93 of fatal COVID-19 lungs and reveals the complex spatial cellular heterogeneity,
94 organization, and interactions that characterize COVID-19 lung pathology.

95

96 **Results**

97 **Spatial single-cell transcriptome analysis, cell segmentation, cell typing, and** 98 **spatial mapping of cells.**

99 Postmortem lung tissues from five COVID-19 autopsies and one postmortem
100 case without COVID-19 were subjected to SSCTA (Fig. 1A). All five COVID-19 cases
101 contracted SARS-CoV-2 in the first wave of the pandemic and had underlying
102 conditions [9], including hypertension (cases 1-3), HIV infection and asthma (case 2),
103 and Parkinson's and chronic kidney diseases (cases 4 and 5). Hematoxylin and eosin
104 (H&E) stains revealed various degrees of diffuse alveolar diseases (DAD), pulmonary
105 thromboembolism, and lymphocytic infiltration in all cases (Fig. S1). Tissues 1 and 2 (1-
106 2C and 2-1A) had prominent organizing pneumonia (OP) or organizing diffuse alveolar
107 damage while edema, hyaline membrane, and fibrin clot or microthrombi were
108 prominent in tissues 3, 4, and 5 (3-1A, 4-3B and 5-3B). We designed probes for
109 detecting the SARS-CoV-2 genome and 221 cellular genes covering markers of
110 common lung parenchymal and immune cells, and immune and inflammatory genes
111 induced by viral infections (Table S1). Following hybridization and gene decoding by *in-*
112 *situ* sequencing, we stained the tissues with 4',6-diamidino-2-phenylindole (DAPI) (Fig.
113 S2) to facilitate cell segmentation (Fig. S2).

114 A workflow was developed to analyze the SSCTA data (Fig. 1B). We detected
115 869,453 to 3,424,675 reads in the six lung tissues for a total of 10,414,863 reads (Table
116 S2 and Fig. S3A). Using the Baysor algorithm [10], we segmented ~89%-95% of reads
117 into cells based on DAPI staining and the spatial distribution of reads (Fig. S4). We
118 identified 186,659 to 470,294 cells for each sample for a total of 1,719,459 cells in these
119 tissues (Table S2 and Fig. S3B). Over 99% of the cells harbored at least 5-15 reads
120 (Fig. S5). We further filtered the cells deemed low quality (see Methods) and retained a
121 total of 779,137 cells for the subsequent analyses.

122 We summarized the reads for each gene and normalized the gene reads of
123 segmented cells using *scTransform* [11]. We assigned cell types to 70-84% of the
124 segmented cells based on the expressions of cell type-specific markers (Table S1) and
125 identified a total of 18 cell types including 11 types of parenchymal cells and 7 types of
126 immune cells in all six tissues (Fig. 1C and S6). We used Uniform Manifold
127 Approximation and Projection (UMAP) to visualize the relationship of gene expressions
128 of individual cells associated with different cell types in all tissues (Fig. 1D and S7).
129 There were negligible batch differences as cells from different samples mixed well in
130 individual cell clusters (Fig. 1D and S7). We noticed separated clusters for major
131 parenchymal cells including alveolar cells (ACs) and fibroblasts. By contrast, immune
132 cells were grouped together and mixed with vascular endothelial cells (VECs) in several
133 clusters (Fig. 1D). The poor separation of immune cell types was largely due to highly
134 expressed immunoglobulin kappa light chain (IGKC) and cathepsin L (CTSL) in these
135 cell types (Fig. S8).

136 We then mapped the individual cells to their spatial locations in the tissues (Fig.
137 S9) and performed the neighborhood cell type composition (NCTC) analysis by
138 computing a vector of 18 cell-type percentages in the neighborhood of individual cells.
139 NCTC reveals spatial variations of the local cell type composition and informs local
140 interplays among cell types. In agreement with the observed pathology that showed
141 DAD in all COVID-19 tissues (Fig. S1), NCTC uncovered disorganized distributions of
142 various cell types, especially the major parenchymal cells such as ACs, VECs, and
143 fibroblasts (Fig. 1E, S1, and S10-S14). In contrast, organized structures and orderly
144 distributions of these cell types were observed in the non-COVID-19 tissue (PBC-PR)
145 (Fig. 1E, S1, and S15). Examination of regions with blood vessels revealed the lining of
146 VECs along the vessels together with other vessel-associated cells including ACs,
147 fibroblasts, and smooth muscle cells (SMCs) (Fig. 1E and S16). Furthermore, we
148 observed abundant infiltrating immune cells including macrophage and monocytes
149 (MMs), natural killer (NK) cells, and T- and B-cells along regions of blood vessels (Fig.
150 1E and S10-S14). We also observed the expected cell compositions of other structures
151 including bronchiole, capillary, and endothelium (Fig. S17). These results validated the
152 marker-based cell typing approach.

153

154 **SARS-CoV-2 infection alters the cell compositions of major parenchymal cells**
155 **and induces immune infiltrations.**

156 In agreement with the results of our previous study [9], we found SARS-CoV-2
157 reads in diverse cell types with infection rates ranging from 0.6% to 5% except that no
158 infected cell was detected in the small number of erythrocytes (55) identified in tissue 1

159 (Fig. 1D, 1F, S7 and Table S3). Most infected cells were identified as ACs, fibroblasts,
160 VECs, and MMs as they were the major cell types in the COVID-19 tissues (Fig. 1F).

161 Consistent with the tissue pathology, we observed significant alterations in the
162 compositions of different cell types in COVID-19 tissues compared to the non-COVID-
163 19 tissue (Fig. 1E and 1F). Among the parenchymal cells, there were reduced numbers
164 of ACs from 44.08% to 12.81-28.23% and SMCs from 5.22% to 1.72-3.05%, and
165 increased numbers of epithelial cells (ECs) from 2.08% to 2.40-8.42%, ionocytes from
166 0.22% to 0.41-1.36% and basal cells from 0.25% to 0.31-1.58%, suggesting their likely
167 involvements in COVID-19 lung pathology (Fig. 1E, 1F, and Table S3). Furthermore, we
168 observed increases in cell numbers of most types of the identified immune cells in
169 COVID-19 tissues (Fig. 1E, 1F, and Table S3). In particular, there were increased
170 inflammatory cells including MMs from 9.4% to 17.51-21.37% and NK cells from 1.00%
171 to 2.32-9.19%, and adaptive immune cells including T cells from 2.40% to 4.34-6.81%
172 and B cells from 1.91% to 2.70-10.51%, which were consistent with the reported
173 inflammatory and cellular immune response following SARS-CoV-2 infection [12].
174 However, these changes were more subtle for some cell types in tissue 1, which had
175 the least infected cells and mildest pathological manifestations with the best integrity of
176 parenchymal cells among all COVID-19 tissues (Fig. 1E, 1F, S1, and S10).

177

178 **SARS-CoV-2 infection induces global differential gene expressions that marked**
179 **pathological damages and inflammation with spatial cellular features.**

180 We examined the differential gene expression between COVID-19 and non-
181 COVID-19 lung tissues, and identified 9 upregulated and 10 downregulated genes,

182 respectively (Fig. 2A, first panel). Comparison of SARS-CoV-2-infected cells in COVID-
183 19 tissues with all cells in the non-COVID-19 tissue confirmed the differential
184 expressions in 16 of these 19 genes (Fig. 2A, second panel). Interestingly, differential
185 gene expressions were also observed in 18 of these 19 genes between uninfected cells
186 in COVID-19 tissues and all cells in the non-COVID-19 tissue (Fig. 2A, third panel). In
187 contrast, there were only 3 differentially expressed genes between SARS-CoV-2-
188 infected and -uninfected cells in the COVID-19 tissues (Fig. 2A, fourth panel). These
189 results indicated that there were strong indirect effects such as those mediated by
190 cytokines and complement activation induced by SARS-CoV-2 infection that likely
191 contributed to the dysregulated gene expressions and pathology in COVID-19 lung
192 tissues. Thus, we focused on comparing COVID-19 tissues with the non-COVID-19
193 tissue in subsequent analyses of dysregulated genes.

194 The expressions of the 19 dysregulated genes in different cell types and their
195 tissue distributions had significant variations suggesting their complex involvements in
196 different aspects of SARS-CoV-2 infection and COVID-19 lung pathology (Fig. 2B, 2C,
197 S8, and S18-S23). We determined the contributions of individual cell types to the
198 expressions of these genes across all the tissues (Fig. 2D). Of the 19 genes, 10 of them
199 were cell markers (Table S1). All 6 parenchymal cell markers including SFTPC,
200 SFTPA1, and advanced glycosylation end product (AGE) receptor (AGER) for ACs,
201 INMT for fibroblasts, smooth muscle actin alpha 2 (ACTA2) for SMCs, and claudin 5
202 (CLDN5) for VECs were downregulated, and mainly expressed in their respective cell
203 types (Fig. 2A, first panel, 2C, 2D, S8 and S18-S23), of which ACs and SMCs had
204 decreased cell numbers in COVID-19 tissues (Fig. 1E, 1F and S7). Both SFTPC and

205 SFTPA1 are implicated in lung homeostasis and functions, and their mutations and
206 dysregulation are associated with pulmonary fibrosis [13-15]. Additionally, SFTPA1, a
207 C-type lectin, which binds to specific carbohydrate moieties on lipids and the surface of
208 microorganisms, is essential in the defense against respiratory pathogens [16-18] while
209 the pulmonary-associated surfactant protein C encoded by SFTPC is a marker for
210 COVID-19 patients with high viral loads [19]. AGER, predominantly expressed in ACs
211 (Fig. 2C), is a multiligand receptor interacting with AGE and other molecules implicated
212 in lung homeostasis, development and inflammation, and certain diseases such as
213 diabetes and Alzheimer's disease, and regulates diverse pathways including MyD88-
214 dependent, nuclear receptors, TNF- α , ERK1/2 and p38 MAPK, and p53/TP53 pathways
215 [20-23]. Following interaction with S100A12, AGER triggers the activation of
216 mononuclear phagocytes, lymphocytes, and endothelium by generating key pro-
217 inflammatory mediators [24]. Indeed, AGER-related pathways are activated by SARS-
218 CoV-2 infection and are implicated in the COVID-19 lung pathology [25, 26]. ACTA2
219 encodes a smooth-muscle actin involved in lung functions including cell motility, tissue
220 structure and integrity, and intercellular signaling [27]. Dysregulation of ACTA2 is linked
221 to a variety of vascular diseases as well as multisystemic smooth muscle dysfunction
222 syndrome [28, 29]. CLDN5 is an integral membrane protein and component of tight
223 junction strands regulating the integrity of epithelial or endothelial cell sheets, and
224 immune cell transmigration [30-32]. SARS-CoV-2 infection suppressed CLDN5
225 expression contributing to the disruption of respiratory vascular barriers [33]. Thus,
226 downregulations of parenchymal cell markers including SFTPC, SFTPA1 and AGER in

227 ACs, ACTA2 in SMCs, and CLDN5 in VECs might be involved in SARS-CoV-2 infection
228 and COVID-19 lung pathology (Fig. 2D).

229 Several other downregulated genes including caveolin 1 (CAV1) and alpha-2-
230 macroglobulin (A2M) are implicated in numerous lung functions (Fig. 2A). CAV1, a
231 component of caveolae involved in multiple pathways such as integrins-mediated and
232 Ras-ERK signaling, is essential for lung functions and during the host response to
233 infections [34, 35]. A2M is an inhibitor of broad spectrum of proteases including trypsin,
234 thrombin, and collagenase [36, 37]. It disrupts inflammatory cascades by inhibiting
235 inflammatory cytokines, is implicated in Alzheimer's disease, and regulates extracellular
236 matrix organization and platelet cytosolic Ca²⁺ [36, 37]. CAV1 and A2M were
237 downregulated and mainly expressed by ACs, fibroblasts, VECs, and MMs (Fig. 2A, first
238 panel, 2D, S8, and S18-S23), of which ACs and fibroblasts had decreased while MMs
239 had increased cell numbers in COVID-19 tissues (Fig. 1F).

240 Three upregulated immune marker genes including complement component C1q,
241 A chain (C1QA) and B chain (C1QB), and neural cell adhesion molecule 1 (NCAM1) are
242 involved in innate immune response and inflammation (Fig. 2A, first panel) [38, 39].
243 C1QA and C1QB were predominantly expressed in MMs (Fig. 2D, S8 and S18-S23).
244 SARS-CoV-2 infection induced robust complement activation, contributing to tissue
245 damage and COVID-19 lung pathology [40-42]. Both cathepsin L (CTSL) and granzyme
246 K (GZMK) could be involved in complement activation [43, 44]. CTSL was induced after
247 SARS-CoV-2 infection and enhanced SARS-CoV-2 infection [45] while GZMK, a serine
248 protease from the cytoplasmic granules of cytotoxic lymphocytes (CTL) and NK cells
249 that recognize and lyse specific target cells [46], could limit the spread of SARS-Co-V-2.

250 Both CTSL and GZMK were upregulated and mainly expressed by ACs, fibroblasts,
251 MMs, and VECs while CTSL exhibited a comparable expression level but with
252 extremely high levels in localized regions in COVID-19 tissues (Fig. 2A, 2B, 2C, 2D, S8
253 and S18-S23). NCAM1, the marker of NK cells, is a member of the immunoglobulin
254 superfamily involved in cell-to-cell interactions as well as cell-matrix interactions [47].
255 The upregulations of C1QA, C1QB, CTSL, GZMK, and NCAM1 were consistent with the
256 increased numbers of MMs and NK cells in COVID-19 tissues (Fig. 1F, S8, and S18-
257 S23). Thus, increased infiltrations of MMs and NK cells were likely involved in COVID-
258 19 lung complement activation and inflammation.

259 Two immune-modulating cytokines were upregulated including colony-stimulating
260 factor 3 (CSF3), a member of the IL-6 superfamily of cytokines that controls the
261 production, differentiation, and function of granulocytes involved in the innate immune
262 response [48, 49], and inducible T cell costimulator ligand (ICOSLG or B7-H2) involved
263 in positive regulation of interleukin-4 production and CD28 signaling in T-helper cells
264 [50, 51]. The major cells that expressed CSF3 and its receptor CSF3R, as well as
265 ICOSLG and its receptor ICOS, were ACs, fibroblasts, VECs, and MMs (Fig. 2D).

266 Numerous other upregulated genes in COVID-19 tissues are involved in
267 inflammatory and immune responses (Fig. 2A). Leukocyte-specific transcript 1 (LST1), a
268 myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine
269 phosphatases SHP-1 and SHP-2 to the plasma membrane, inhibits the proliferation of
270 lymphocytes, and its expression is enhanced by lipopolysaccharide (LPS), interferon-
271 gamma (IFN- γ) and bacteria [52, 53]. Immunoglobulin kappa light chain (IGKC) is
272 essential for antibody production but is also expressed in non-lymphoid cells [54-56].

273 Both LST1 and IGKC were mainly expressed in ACs, fibroblasts, VECs and MMs (Fig.
274 2B-E, S8 and S18-S23), which might mediate dysregulation of immune cells in COVID-
275 19 lung tissues. Finally, fibulin 1 (FBLN1), a secreted glycoprotein incorporated into a
276 fibrillar extracellular matrix in a calcium-dependent manner and mediates platelet
277 adhesion via binding fibrinogen [57, 58], was mainly expressed in ACs, fibroblasts,
278 VECs, and MMs (Fig. 2D).

279 We examined differential gene expressions in cell types that had significant
280 changes in cell numbers (Fig. 1F). Compared to non-COVID-19 tissue, ACs from
281 COVID-19 tissues had 20 differentially expressed genes, of which 14 were identified at
282 the whole tissue level (Fig. 2A, first panel and 2E). The most upregulated genes were
283 LST1, CTSL, IGKC, ICOSLG, C1QB, GZMK, and NCAM1 while the most
284 downregulated genes were SFTPC, A2M, SFTPA1, CLDN5, and CAV1 (Fig. 2E), which
285 likely contribute to the decreased cell numbers in COVID-19 tissues (Fig. 1F). Several
286 differentially expressed genes were also identified in fibroblasts, VECs and ECs (Fig.
287 2E). Among the immune cells, MMs had the most differentially expressed genes
288 including upregulation of C1QB, NCAM1, and IGKC, and downregulation of A2M, CD68,
289 TYROBP and PRG4 (Fig. 2E).

290

291 **Spatial analysis identifies regions with high SARS-CoV-2 infection rates that**
292 **match high cell densities, high levels of viral entry-related factors, and localized**
293 **pathology.**

294 Even though we did not observe notable global differences in gene expression
295 between infected and uninfected cells within each COVID-19 tissue, the spatial nature

296 of the SSCTA permitted the identification of the local impact of SARS-CoV-2 infection
297 on lung pathology. We performed the local infection rate analysis to examine the spatial
298 distributions of local SARS-CoV-2 infection (Fig. 3A) and identified regions with high
299 and low infection rates in each tissue (Fig 3B; local Moran's I, p-value < 0.05). SARS-
300 CoV-2 infects host cells by binding to its entry receptor, angiotensin-converting enzyme
301 2 (ACE2), and subsequent engagement of host proteases and other entry-related
302 factors including FURIN, transmembrane protease, serine 2 (TMPRSS2), and neuropilin
303 1 (NRP1) [59]. We assessed the spatial correlation between high-infection regions and
304 cells expressing transcripts of these viral entry-related proteins. We found a significant
305 correlation between high infection rates and high expressions of ACE2, FURIN,
306 TMPRSS2, and NRP1 (Fig. 3C; bivariate local Moran's I, p-value < 0.05), supporting the
307 essential roles of these cellular proteins in SARS-CoV-2 infection in lung tissues.

308 Previous studies reported increased densities of both parenchymal and immune
309 cells in COVID-19 lung tissues [6]. Here, we observed a positive spatial correlation
310 between cell densities and SARS-CoV-2 infection rates especially in tissues 1-4 (Fig.
311 3D, Table S4), suggesting that increased cell densities might be associated with high
312 infection rates. We segmented regions with high infection rates and high cell densities
313 (HIHD) (Fig. 3E; bivariate local Moran's I, p-value < 0.05). Compared with H&E staining
314 (Fig. S1), we found a close association between HIHD and OP, which was most
315 prominent in tissues 1 and 2, as well as lymphocytic and immune infiltration, which was
316 most severe in tissues 3 and 4 (Fig. 3E). Both are the most common lung pathological
317 manifestations in COVID-19 lungs [12]. Hence, high infection rates might cause
318 persistent damages to the lung tissues, resulting in the infiltration of immune cells, and

319 increased wound repair and fibrosis [60, 61]. We also observed HIHD areas adjacent to
320 blood vessels in tissues 1 and 3 (Fig. 3E and S1), which might be due to the homing of
321 the circulating virus and immune cells in the bloodstream to these sites or that these
322 cells were more susceptible to SARS-CoV-2 infection [9, 62].

323

324 **Regions with high SARS-CoV-2 infection rates have unique cellular and gene**
325 **expression features.**

326 We next examined cell type compositions of the high and low SARS-CoV-2
327 infection regions. Compared to low-infection regions across the tissues, the
328 compositions in high-infection regions exhibited significant increases in fibroblasts,
329 echoing the observed OP in HIHD areas, and an increase in ACs, possibly due to the
330 proliferation of ACs response to injury repair of alveoli and alveoli capillaries (Fig. 3E
331 and 4A). However, there were decreases in ECs and VECs, which might reflect the
332 damages caused by the infection (Fig. 3E and 4A). These results suggested that high-
333 infection regions might suffer more damages. However, except for T cells and
334 granulocytes, the compositions of major immune cell types including MMs between high
335 and low infection regions remained similar (Fig. 4A), suggesting induction of a broad
336 immune infiltration by SARS-CoV-2 infection, as well as the observed broad impact on
337 the tissue-wide gene expression (Fig. 2A).

338 The patchwork of high infection regions in tissue 1 prompted us to inspect
339 patterns of local cell-type compositions. Interestingly, NCTC analysis showed three
340 clusters in high-infection regions, of which two were distinctly enriched with prominent
341 local compositions of fibroblasts and ACs, respectively (Fig. 4B). Examining their spatial

342 distributions confirmed a negative *in-situ* correlation between local compositions of
343 fibroblasts and ACs (-0.6, Pearson correlation), with regions showing high (low)
344 compositions of fibroblasts accompanied with low (high) compositions of ACs (Fig. 4B
345 and C). Strikingly, the local regions with high fibroblasts but low ACs were mostly
346 annotated OP regions (Fig. S1).

347 We next investigated the gene expression patterns in the high- and low-infection
348 regions. Compared with the normal tissue, the high and low infection regions presented
349 highly consistent differential expression patterns as they shared 18 of the 20
350 differentially expressed genes (Fig. 4D), confirming the strong indirect effect of SARS-
351 CoV-2 infection (Fig. 2A). One of the two uniquely differentially expressed genes in high
352 infection regions was again cytokine CSF3, which was upregulated in all infected
353 tissues. We, therefore, investigated spatial co-expression of CSF3 and its receptor
354 CSF3R (Fig. 3F) and found that their co-expression patterns also presented spatial
355 correlations in high infection regions (Fig. 3G; bivariate local Moran's I, p-value < 0.05),
356 suggesting that the CSF3-CSF3R axis might modulate the immune response in high-
357 infection regions. In contrast to the consistent differentially expressed patterns of both
358 high- and low-infection regions when compared with the normal control, direct
359 comparison between high- and low-infection regions revealed distinct differentially
360 expressed patterns. Particularly, we observed, in high- vs. low-infection regions,
361 upregulation of AC markers SFTPA1 or SFTPA2 in tissues 1, 3, and 5 (Fig. 4E and 2C)
362 and fibroblast markers COL1A1 or COL1A2 in all COVID-19 tissues (Fig. 4E and 4F),
363 despite that SFTPA1 and COL1A2 displayed down-regulation in either high- or low-
364 infection regions in COVID-19 tissues when compared to the normal tissue (Fig. 4D).

365 The increased expressions of these AC and fibroblast markers were also consistent
366 with the observed increases in ACs and fibroblasts in high-infection regions in the
367 corresponding tissues (Fig. 4A). Cell type-specific differential expressions further
368 confirmed the upregulation of SFTPA1 or SFTPA2 in ACs, and COL1A2 in fibroblasts in
369 infected tissues (Fig. 4E and S24). However, different cell types exhibited complex
370 differential expression patterns between high vs. low infection regions in individual
371 COVID-19 tissues (Fig. S24), likely due to the distinct COVID-19 pathologies or stages
372 associated with the individual infected tissues.

373

374 **Sparse non-negative matrix factorization analysis identifies seven cell**
375 **composition signatures that recapitulate different healthy and disease statuses.**

376 Although different DAD phases can inform COVID-19 severity, they are
377 confounded by many factors including the underlying conditions of the patients as
378 illustrated by our five COVID-19 cases (Fig. S1). Importantly, the complex tissue
379 microenvironments of parenchymal and immune cells associated with different stages of
380 DAD within and across tissues have not been well characterized. Therefore, we
381 determined the extent to which tissue-independent and tissue-specific spatial patterns in
382 spatially resolved cell-type compositions are associated with different DAD stages. For
383 this purpose, we performed the sparse non-negative matrix factorization (SNMF) [63] of
384 the NCTC vectors of all cells in all tissues. SNMF decomposed these NCTC vectors into
385 a sparse linear combination of cell-type composition signatures that define spatial cell-
386 type patterns in these tissues. We obtained a factorization of seven NCTC signatures
387 after assessing the compactness and biological meanings of the factorization results for

388 different maximum numbers of factors (Fig. 5). Close examination of cell type
389 compositions of the signatures (Fig. 5A and Table 5) and their spatial prevalence across
390 all tissues (Fig. 5B) defined by the factor loading revealed their associations with normal
391 structures, and broad and tissue-specific infection. Specifically, Signature 1 likely
392 defined the cell type composition of “normal-like lung alveoli” because it has 56.4%
393 ACs, 18.5% VECs, 11.9% fibroblasts, and 5.3% SMs, which were comparable to the
394 percentages of the non-COVID-19 tissue (Fig. 1F and Table S3). Thus, the high-loading
395 regions of Signature 1 in COVID-19 tissues might mark the less damaged regions.
396 Naturally, the non-COVID-19 tissue had a high prevalence of Signature 1 (Fig. 5B and
397 S25). Tissue 1 had the highest prevalence of Signature 1 among all COVID-19 tissues
398 reflecting its least damaged pathology, followed by tissue 4, 3, 2, and 5 (Fig. 5B, S1,
399 and S25). Signature 2 described a composition of 61% ECs, 14% ciliated cells, and
400 10% basal cells. It had sparse but high-intensity loadings in localized regions identified
401 as bronchial tubes (Fig. 5B and S1). In contrast to Signatures 1 and 2 which
402 characterized cell-type compositions of normal structures, Signature 3 captured the
403 “broad immune infiltration” as it contained 28.6% B cells, 22.3% MMs, 17.5% T cells,
404 9.6% granulocytes, and 8.7% ECs (Fig. 5A and Table S5). As expected, it was the least
405 common in the non-COVID-19 tissue (Fig. 5B and S25). Its loading distributions in
406 COVID-19 tissues were consistent with the lowest immune infiltration in tissue 1,
407 followed by 4, 3, 2, and 5 (Fig. 5B and S25), closely corroborating the order of damage
408 revealed by Signature 1. Trajectory analysis of the cell type compositions with
409 Signatures 1 and 3 using *Slingshot* [64] defined a trajectory of reduced normal alveoli
410 and increased immune infiltration from the non-COVID-19 tissue to tissue 1, 4, 3, 5, and

411 2 (Fig. 5C), which was in agreement with the order of their increased severity of
412 pathology observed in H&E staining (Fig. S1). Remarkably, Signatures 4 to 7 captured
413 four distinct types of immune microenvironments or niches in these COVID-19 tissues.
414 Signature 4 was characterized by high ACs (64.8%) with MMs (27.3%), likely reflecting
415 the infiltration of alveolar MMs and proliferation of ACs in wound healing, all of which
416 are features of exudative DAD [65]. The relatively higher prevalence of Signature 4 in
417 the less severe tissues 1 and 4 suggested its association with early phases of DAD (Fig.
418 5B and S25). There were also overlaps in regions with higher loadings of Signature 4
419 with the annotated regions of immune infiltration in the H&E image in tissue 4 (Fig. 5B
420 and S1). Signatures 5 and 6 depicted inflammations around VECs, where Signature 5
421 was associated with extensive infiltration of MMs (46.7%) and T cells (8.7%) around
422 VEC (26.3%), whereas Signature 6 was associated with substantial infiltration of NK
423 cells (31.8%) and granulocytes (13.6%) around VECs (27.6%) and ECs (12.2%). These
424 results were consistent with the influx of MMs and NK cells (Fig. 1E and F), which was
425 likely due to the activation of complement and coagulation systems (Fig. 2A and C),
426 resulting in damages and therefore reduced numbers of ACs and VECs (Fig. 1E and F).
427 Signature 5 was more common in the less severe tissues 1, 3 and 4 but Signature 6
428 appeared predominantly in 3 (Fig. 5B and S25), particularly in low infection region (Fig.
429 3A). Indeed, lymphocytic infiltrations were also identified in the regions associated with
430 Signatures 5 and 6 (Fig. S1). Signature 7 denotes extremely high fibroblasts (73.4%)
431 with infiltration of MMs (15.8%). Advanced disease in COVID-19 patients often has an
432 excessive accumulation of fibroblasts and may develop pathological fibrosis due to
433 chronic inflammation from the infiltrated immune cells and dysregulation of the

434 extracellular matrix triggered (ECM) remodeling [66]. As expected, there was a high
435 correlation between the COL1A1 expression level (Fig. 4F) with Signature 7. The
436 loadings of this signature were high in tissues 1 and 2, which were annotated as OP
437 regions, and in tissue 5, which were annotated as fibrin and hyaline membrane in
438 addition to OP regions (Fig. 5B, S1 and S25), suggesting a connection with OP, fibrin
439 and hyaline membrane.

440

441 **Unique cell composition signatures define two separate pathological trajectories.**

442 We then applied Signatures 4 to 7 to delineate the trajectories of DAD
443 characterized by the immune responses against viral infection. We added Signature 1
444 “normal-like alveoli” so that the non-COVID-19 tissue could be included as a reference.
445 We used these 5 signatures to redefine the landscape of spatially resolved cell type
446 compositions in these tissues. The UMAP visualization (Fig. 6A) recapitulated the tissue
447 severity inferred by Signatures 1 and 3 (Fig. 5C) but presented more complex patterns,
448 with each immune signature defining a largely distinct group of cell populations (Fig.
449 6B). We applied *Slingshot* to infer pseudo-progressions of cells defined by these
450 signatures and identified two trajectories (Fig. 6A). Clustering of cells based on pseudo-
451 time values further segmented the trajectories into 6 stages (Fig. 6A). At the onset, the
452 two trajectories shared a common path including stages T1 and most T2, which
453 traversed the cells enriched by Signature 1 “normal-like alveoli” and Signature 4 “ACs
454 with MMs infiltration” in T1 and then those enriched by Signature 4 and Signature 5
455 “VECs with MMs infiltration” in T2 (Fig. 6A). These stages were consistent with the less
456 damaged presentations of tissues 1 and 4 (Fig. 6D and S1) and showed a reduction of

457 ACs due to likely lung injury and an increase of MMs possibly promoted by innate
458 immune responses (Fig. 6C). Inspecting associated tissue regions in the H&E images
459 showed characteristics of early DAD manifested by shedding of ACs, capillary leakage,
460 lymphocytic/immune infiltration, and yet preserved alveoli structure (Fig. 6D and E, T1
461 and T2). After the shared section, the trajectories diverged into two paths. The first path
462 (Trajectory A) included T3a and T4a and progressed through cells mostly from tissues 3
463 and 4 enriched in Signature 5 “VEC with MMs infiltration” ending in Signature 6 “VEC
464 with NK cell infiltration”, which was almost exclusively from tissue 3 (Fig. 6A, B and D).
465 We observed a persistent decrease in ACs but an increase in VECs, NK cells and B
466 cells (Fig. 6C). The H&E staining of tissue regions for T3a and T4a showed hyaline
467 membrane, fibrin, lymphocytic infiltration, and collapsed alveoli and capillary structure
468 (Fig. 6E, T3a and T4a, and S1). These features are consistent with a more advanced
469 DAD. The close association of this path with tissues 3 and 4 suggested that they
470 encompassed similar DAD-related tissue patterns and immune niches. Indeed, the
471 postmortem report showed similar findings for these two patients including bilateral
472 pulmonary consolidation [9].

473 The second path (Trajectory B) included two stages, i.e., T3b and T4b, which are
474 enriched by Signature 6 in T3b and Signature 7 “high fibroblasts with MMs infiltration” in
475 T4b highlighted by increased fibroblasts and immune infiltration of especially MMs (Fig.
476 6A, B, and C). Their associated tissue regions were mostly in tissues 1, 2, and 5 (Fig.
477 6D), suggesting potentially similar DAD tissue patterns and underlying immune niches
478 in these tissues. The postmortem findings indeed revealed massive pulmonary emboli
479 that were the main cause of death for cases 1 and 2 [9]. Close examination of these

480 regions in the H&E staining showed edema, increased fibrin, and OP (Fig. 6D, E, T3b
481 and T4b, and S1), which are pathological signatures of DAD. There was a striking
482 association between regions in tissues 1, 2 and 5 in T4b with the identified OP, fibrin
483 and hyaline membrane regions and a significant positive correlation between the
484 progression of Trajectory B and cell density (0.504, Spearman correlation, p -value <
485 0.05) suggesting a more advanced stage of T4b than T3b with tissue 1 manifested in a
486 more localized while tissues 2 and 5 in a more systematic manner. These results
487 demonstrated a high degree of inter and intra-tissue heterogeneity in DAD-associated
488 patterns. While tissue 1 contained regions affiliated with both trajectories, tissues 2 and
489 5 were mostly associated with the trajectory featured by high fibroblasts and their
490 reorganization, and tissues 3 and 4 were with the trajectory featured by increased VEC
491 and immune infiltration.

492 Next, we investigated the genes whose expressions in a cell type were correlated
493 with the trajectories. We found 53 and 67 genes significantly correlated with Trajectory
494 A and B in at least one cell type, respectively (Spearman correlation, p -value<0.05,
495 permutation test; Table S6). In both trajectories, we obtained a negative correlation for
496 ACs marker SFTPC in ACs (Fig. S26A, S26B, Table S6, and Table S7), suggesting a
497 decrease in its expression, which echoes the reductions in ACs in both trajectories (Fig.
498 6C). We also found a positive correlation of NCAM1 in NK cells with Trajectory A and
499 positive correlations of COL1A1 in Fibroblasts and C1QB in MMs with Trajectory B (Fig.
500 S26A, S26B, Table S6, and Table S7), all of which were consistent with the observed
501 changes of cell type compositions and DAD pathologies along the trajectories (Fig. 6C).

502 To gain further insight into potential ligand-receptor interactions that underlie the
503 immune patterns associated with the trajectories, we correlated the ligand-receptor co-
504 expressions with the trajectories. We found that CD40LG-CD40, CD80-CD28 and
505 CXCL10-CXCR3 had the highest positive correlations with Trajectory A in all key cell
506 types including especially VECs, ACs and Fibroblasts (Fig. S26C) while CD40LG-CD40,
507 CSF3-CSF3R and CXCL10-CXCR3 were the top positive correlated pairs with
508 Trajectory B in ACs, Fibroblasts, VECs and MMs (Fig. S26D). Thus, these ligand-
509 receptor pairs might contribute to the chemoattraction of the immune cells as a result of
510 SARS-CoV-2 infection.

511

512 **IL6-STAT3 and TGF- β -SMAD2/3 pathways mediate COVID-19 lung fibrosis and**
513 **organizing pneumonia.**

514 Because Trajectory B progressed into tissue regions that manifested extensive
515 OP, we investigated the spatial patterns and molecular signatures associated with OP,
516 which was mostly observed in tissues 1 and 2 and to a less extent in tissue 5, which
517 also contained fibrin and hyaline membrane (Fig. 7A and S1). Analysis of cell
518 compositions in regions with OP revealed an overall increase in cell density, and
519 obvious decreases in cell numbers of ACs and VECs but an increase in cell numbers of
520 fibroblasts compared to other regions in the same tissues and the non-COVID-19 tissue
521 (Fig. 7B, C and D). As in the whole tissues, we observed downregulations of AGER,
522 CAV1, SFTPA1, SFTPC, and A2M, and upregulation of IGKC in OP regions compared
523 to the normal tissue (Fig. 7E). The changes of AGER, SFTPA1, SFTPC, and A2M were
524 primarily observed in fibroblasts, MMs and VECs with downregulation of A2M also being

525 observed in ACs (Fig. 7F, G and H). The most striking observation is the upregulation of
526 genes encoding for collagen type I alpha 1 and 2 chains (COL1A1 and COL1A2) in OP
527 in both tissues compared to the normal tissue or to regions without OP in the same
528 COVID-19 lung tissues (Figure 7E and G). Furthermore, both COL1A1 and COL1A2
529 were upregulated in fibroblasts in OP regions compared to fibroblasts from either
530 normal tissue or non-OP regions from the same tissue (Fig. 7G, H and I). COL1A1 and
531 COL1A2 form the triple helix of a fibril-forming collagen, which is essential for lung
532 homeostasis. Dysregulation of COL1A1 and COL1A2 leads to lung inflammation and
533 fibrosis [67, 68]. Both COL1A1 and COL1A2 were mainly expressed in fibroblasts (Fig.
534 7G and 7H), whose cell numbers were doubled in OP regions in both tissues compared
535 to non-OP regions (Fig. 7D). Interestingly, the expression levels of COL1A1 and
536 COL1A2 were highly heterogeneous in the individual cells in OP regions with extremely
537 higher levels in 10-20% of the fibroblasts, which were absent in fibroblasts in non-OP
538 regions or any other types of cells in the same COVID-19 tissues (Fig. 7J). COL1A1 and
539 COL1A2 were not expressed in high levels in any types of cells in normal lung tissue
540 (Fig. 7J). These results indicated that COVID-19 OP regions had severe dysregulation
541 of fibroblasts with upregulation of COL1A1 and COL1A2, and abnormal ACs and VECs
542 as a result of downregulation of AGER, SFTPA1, and SFTPC.

543 To further confirm that increased expressions of COL1A1 and COL1A2 were
544 hallmarks of COVID-19 OP, we examined their expressions in different cell types in
545 single-cell RNA-seq (scRNA-seq) data from COVID-19 lung tissues [4]. Consistent with
546 our observation, we found that COL1A1 and COL1A2 expressed mainly in fibroblasts
547 and also showed varying expression levels (Fig. S27A). Specifically, they showed a

548 higher expression level in a subset of fibroblasts enriched with myofibroblasts ($p <$
549 0.001, Gene Set Enrichment Analysis (GSEA): Fig. S27A and B). Myofibroblasts are
550 differentiated fibroblasts, whose dysregulation may lead to idiopathic pulmonary fibrosis
551 (IPF) including COVID-19 lung fibrosis, a lung disease that exhibits OP [69-71]. To
552 provide a linkage between the OP regions and IPF, we examined the scRNA-seq data
553 from lung tissue patients with IPF and nonfibrotic controls [72]. Like in the COVID-19
554 data, we observed a subpopulation of fibroblasts with high expressions of COL1A1 and
555 COL1A2 (Fig. S27C) and they were also enriched in myofibroblasts (p -values <0.001 ,
556 GSEA; Fig. S27D). We further examined the differentially expressed genes in IPF
557 fibroblast cells with high COL1A1 and COL1A2 expressions vs. fibroblast cells with low
558 COL1A1 and COL1A2 expressions or nonfibrotic cells, respectively (Fig. S27E and
559 S27F). The two lists of significant differentially expressed genes (DEGs) were similar (p -
560 values <0.001 , GSEA; Fig. S27G), suggesting that the subpopulation with low COL1A1
561 and COL1A2 expressions could serve as normal control. As a result, we compared the
562 fibroblasts with a high vs. low COL1A1 and COL1A2 expressions in the COVID-19
563 scRNA-seq data and obtained the DEGs (Fig. S27H). These DEGs are enriched by two
564 DEG lists in IPF fibroblasts with high COL1A1 and COL1A2 expressions ($p < 0.001$,
565 GSEA; Fig. S27I and S27J), suggesting that these cells likely had similar molecular
566 characteristics as those in IPF. Indeed, functional enrichment analysis using the
567 Ingenuity Pathway Analysis reported “Pulmonary Fibrosis Idiopathic Signaling
568 Pathways” as the 2nd top-ranked pathway (Fig. S27K). Several other top enriched
569 pathways related to extracellular matrix remodeling were also identified. Examination of
570 the networks of these pathways identified IL6-STAT3 and TGF- β -SMAD2/3 pathways

571 that could directly regulate the expressions of COL1A1 and COL1A2 (Fig. 7K). Multi-
572 color indirect immunofluorescence antibody assay (IFA) staining indeed revealed that
573 cells with a high COL1A1 expression level also had high levels of IL6 receptor-
574 α (IL6R α), phospho-STAT3 (p-STAT3), TGF- β R2 and phospho-SMAD2/3 (p-SMAD2/3),
575 confirming the activation of these pathways and their potential roles in the upregulation
576 of COL1A1 (Fig. 7L). Both IL6 and TGF- β are highly induced, and implicated in fibrosis
577 and lung injury [73, 74] as well as upregulation of COL1A1 and other extracellular matrix
578 proteins in COVID-19 lung tissues [75, 76]. These results demonstrated the important
579 roles of IL6 and TGF- β in the induction of severe COVID-19 lung OP and fibrosis.

580

581 **Discussion**

582 Using *in-situ* sequencing and our spatial single-cell analysis pipeline, we have
583 painted an atlas of cellular and molecular signatures of lung tissues from severe
584 COVID-19 cases. The atlas describes the cellular heterogeneity, organization, and
585 interactions associated with inflammation, damage, and immune responses in COVID-
586 19 tissues. It provides molecular and cellular insights into the mechanisms underlying
587 SARS-CoV-2 infection and the pathological manifestations in COVID-19 lungs.

588 We detected a total of 10,414,863 transcripts in five COVID-19 and one non-
589 COVID-19 lung tissues. Spatial single-cell transcriptomics analysis at this scale for
590 COVID-19 and other pathological conditions is still very limited. We have overcome
591 considerable challenges and developed a pipeline of robust, scalable, interpretable
592 computational tools and visualization methods for targeted and exploratory analyses
593 emphasizing on spatial discovery. The first critical component of this pipeline is a

594 transcript-based cell segmentation strategy that integrates cell nuclei in the matching
595 DAPI staining identified by *CellPose* with spatially localized reads using *Baysor* and
596 iteratively segments reads into cells of potentially different sizes [10, 77]. Using this
597 strategy, we segmented 93% of total transcripts into 1,719,459 cells including 186,659
598 to 470,294 cells for different tissues. A customized filter was further applied to retain
599 only a subset of high-quality cells.

600 Cell typing of these filtered cells based on marker genes showed that SARS-
601 CoV-2 infected all the 18 identified cell types, a result consistent with those of our
602 previous study [9] and others [4]. However, only a small fraction of these cells (<5%) are
603 infected. These results agree with those of genome-wide studies that detected small
604 numbers of viral reads in blood, lung, and nasopharyngeal samples from severe
605 COVID-19 patients [4, 78-81]. Despite the detected low infection rates, SARS-CoV-2
606 inflicts similar effects on the infected and uninfected cells across the tissues as shown
607 by differential expression analysis of genes in infected or uninfected cells in COVID-19
608 tissues against cells in the non-COVID-19 lung tissue (Fig. 2A). Thus, indirect effects
609 such as those induced by the immune response, inflammation, cytokines, and
610 complement activation might play a significant role on lung pathology in COVID-19
611 patients. In fact, we have observed vast pulmonary microthrombi, thrombosis, and
612 immune infiltrations in these COVID-19 lung tissues (Fig. S1). The major parenchymal
613 cells including ACs, fibroblasts, and VECs have the highest numbers of infected cells.
614 The COVID-19 lung tissues have reduced numbers of ACs and SMCs, but an increased
615 number of ECs accompanied by vast immune infiltrations of innate immune cells

616 including MMs, granulocytes, and NK cells, and adaptive immune cells including T and
617 B cells.

618 Despite these global and consistent impacts of SARS-CoV-2 infection on the
619 lungs, there are extensive spatial heterogeneities in addition to varying cell type
620 percentages across the tissues. To reveal spatial dynamics of cellular features
621 presented in considerable spatial discontinuity due to sparse measurements, we
622 adopted a strategy to compute local feature distributions in the neighboring region of the
623 cell with a fixed radius or cell number. This approach assesses the spatial gene
624 expression maps, local infection rates, cell densities, and co-expression maps of ligand-
625 receptor pairs. To further characterize spatial patterns of an individual feature or joint
626 pattern relationship between two features, we extensively applied the Moran's I
627 statistics, a method widely adopted in geoscience but scarcely in spatial transcriptomics
628 analysis. Using these novel strategies, we identified regions with high infection rates,
629 which are found in regions with high cell densities expressing higher levels of SARS-
630 CoV-2 entry-related factors including ACE2, FURIN, TMPRSS2, and NRP1. Thus,
631 SARS-CoV-2 may preferentially infect cells expressing these factors and the infected
632 cells could also aggregate to these high-density regions following infection. Importantly,
633 these regions are mapped to OP (tissues 1 and 2) or regions with fibrin, hyaline
634 membrane, and edema (tissues 3, 4, and 5), and manifest cellular and molecular
635 patterns resembling tissue damage and wound healing including infiltration of immune
636 cells and pattern of fibrosis. We have found that OP harbors high densities of fibroblasts
637 expressing high levels of COL1A1 and COL1A2, a phenomenon common in fibrosis and
638 wound healing, which are unique to OP regions unseen in other regions of COVID-19

639 lung tissues or in the non-COVID-19 tissue. We have identified similar cell populations
640 enriched by myofibroblasts in 10X scRNA-seq data from COVID-19 lung samples and
641 IPF samples, suggesting that SARS-CoV-2 might preferentially infect myofibroblasts or
642 reprogram other cell type(s) into myofibroblasts. Pathway enrichment analysis revealed
643 the enrichment of multiple pathways related to IPF signaling and extracellular matrix
644 remodeling including IL6-STAT3 and TGF- β -SMAD2/3 pathways. Indeed, we have
645 detected high levels of IL6Ra, p-STAT3, TGF- β R2, and p-SMAD2/3 in cells expressing
646 myofibroblast markers in OP regions. These results suggest that SARS-CoV-2 infection
647 might induce aggregation of fibroblasts, and IL6 and TGF- β to promote wound healing
648 in OP regions.

649 To define spatial patterns associated with COVID-19 lung pathology, we
650 performed the NCTC analysis, or the niche analysis, commonly used for probing
651 interactions of cells such as in immune microenvironments. However, the COVID-19
652 tissues contain complex pathology manifestations resulting in highly heterogenous
653 cellular organizations and thus disparate NCTC patterns. To tackle this challenge, we
654 applied SNMF, owing to its scalability and interpretability, to NCTCs of all cells in six
655 tissues to reveal potentially latent features underlying these seemingly less organized
656 NCTCs. We indeed identified 7 latent signatures of spatial cell type compositions that
657 define normal lung structures and SARS-CoV-2 infection-induced immune niches. While
658 many existing studies have revealed the global immune landscape of SARS-CoV-2
659 infection [1, 2, 5], few report spatial signatures of immune niches. We showed that these
660 niches are mostly tissue-independent, but COVID-19 tissues presented heterogeneous
661 distributions of these niches: while tissues 1, 2, 4, and 5 contain multiple types of

662 niches, tissue 3 has predominately a single type. We further drew the connections
663 between these niches and different stages of DAD. Such a linkage prompted us to apply
664 the trajectory analysis to NCTCs of these signatures. While the trajectory analysis is
665 most commonly applied to gene expressions to predict a pseudo-progression of the
666 cells, here, this innovative use of trajectory analysis defined the relative severities of
667 damages among COVID-19 tissues and constructed two different pathological routes of
668 progression in COVID-19 patients. Both routes start with enriched “ACs with MM
669 infiltration” and “VECs with MMs infiltration” niches but Route A is marked by increased
670 numbers of NK cells and granulocytes, likely reflecting complications of microbial
671 infections, while Route B is characterized by increased HIHD and OP, marked by
672 increased fibrosis. Both routes are also correlated with multiple cytokine-cytokine
673 receptor pairs such as CD40LG-CD40 and CXCL10-CXCR3 that are likely to mediate
674 the chemoattraction of the immune cells (Fig. S26C and S26D). By mapping these
675 routes to individual cells, we further revealed considerable inter and intra-tissue
676 heterogeneity in the inferred progression of COVID-19 pathology with tissue 3 and 4
677 associated with Route A, tissue 2 and 5 with Route B, and tissue 1 with both routes.

678 In summary, we have presented an atlas of spatial patterns of different cellular
679 features that characterize SARS-CoV-2 infection, its induced immune infiltrations,
680 inflammation, and damages in severe COVID-19 lungs, in addition to changes in gene
681 expression in multiple cell types, including immune cells and lung parenchymal cells.
682 These results provide insights into the spatial mechanisms at both molecular and
683 cellular levels, which characterize the development of ARDS in COVID-19 patients.
684 Overall, this study demonstrates the power of spatial single-cell transcriptomics and

685 enables spatial computational analyses in the study of COVID-19 lung pathology. The
686 developed innovative methods can benefit spatial single-cell analyses for other healthy
687 and diseased conditions.

688

689 **Methods**

690 **Lung tissue samples**

691 COVID-19 lung tissues were collected from 5 adults with fatal SARS-CoV-2
692 infection by the Autopsy Service of the Department of Pathology, Molecular and Cell-
693 Based Medicine at the Icahn School of Medicine at Mount Sinai, and non-COVID-19
694 lung tissue was obtained from Pitt Biospecimen Core [9].

695

696 **Study approval**

697 Specimens obtained at autopsy do not meet the definition of a living individual
698 per Federal Regulations 45 CFR 46.102, and as such, research using specimens
699 obtained at autopsy does not meet the requirements for Institutional Review Board
700 (IRB) review or oversight under the Icahn School of Medicine Program for the Protection
701 of Human Subjects. The University of Pittsburgh IRB determined that the study is not
702 research involving human subjects as defined by DHHS and FDA regulations and
703 waived of ethical oversight (STUDY20050085).

704

705 **In-situ sequencing (ISS)**

706 HS Library Preparation kit (P/N 1110-02, CARTANA AB, part of 10x Genomics)
707 was used to prepare the library according to the manufacturer's instruction with minor

708 modification [82]. Four μm FFPE tissue sections were baked for 1 hour at 60°C and
709 deparaffinized by incubating in xylene twice for 7 minutes (min) each. The sections were
710 then rehydrated by incubating in 100% ethanol (EtOH) for 5 min, followed by 70% EtOH
711 for 5 min, and nuclease-free deionized distilled water (SH30538.02, HyClone) for 2 min.
712 Sections were then permeabilized by incubating in citrate buffer pH 6.0 (C9999, Sigma
713 Aldrich) for 3 hours at 95°C. Chimeric padlock probes (from 1 custom panel (Table S1)
714 and 4 pre-designed panels: hImmune I1A, hImmune I3D, hLung L1C, hLung L2E,
715 CARTANA AB) directly targeting RNA and containing an anchor sequence as well as a
716 gene-specific barcode were hybridized overnight at 37°C, then ligated overnight at
717 30°C. Quality control of the library preparation was performed by applying anchor
718 probes which labeled by Cy5 to simultaneously detect all rolling circle amplification
719 products from all genes in the panel. All incubations were performed in SecureSeal™
720 hybridization chambers (621502, Grace Biolabs). Slow Fade Antifade Mountant
721 (S36936, ThermoFisher) was used for mounting. All samples passed the quality control
722 and were sent to CARTANA AB (part of 10x Genomics) for *in-situ* barcode sequencing,
723 imaging, and data processing. Briefly, the fluorescent signals for quality control were
724 stripped. Adapter probe pool 1 and a sequencing pool containing 4 different fluorescent
725 labels were hybridized to the *in-situ* libraries to detect gene-specific barcodes. The
726 scanning was fulfilled by using epifluorescence microscopy, and raw data consisting of
727 20x magnification images from 5 fluorescent channels (DAPI, Alexa Fluor® 488, Cy3,
728 Cy5 and Alexa Fluor® 750) and individual z-stacks, were flattened to 2D using
729 maximum intensity projection with a Nikon Ti2 Microscope (software NIS elements)
730 utilizing a Zyla 4.2 camera. In total, 6 sequencing cycles were achieved for full decoding

731 of all designed genes. After image processing, which includes image stitching,
732 background filtering, and a sub-pixel object registration algorithm, true signals were
733 scored based on signal intensities from individual multicolor images. The results were
734 summarized in a CSV file and gene plots were generated using MATLAB. Each ISS
735 spot provided a unique fluorescent barcode identifying the targeted RNA of a gene
736 marker. The experiment generated a map of gene expressions of selected genes
737 recorded on the natural morphology of the tissue at a single-cell level. The metadata
738 generated from the images were further analyzed to obtain data containing the reads
739 and their 2D (X, Y) positions of each gene, and the DAPI images. TissuuMaps [83, 84]
740 was used to visualize spatial read locations of multiple genes against DAPI or histology
741 images.

742

743 **Hematoxylin-eosin staining (H&E) and whole slide scanning**

744 H&E was carried out with the same slides subjected to *in-situ* sequencing using
745 Hematoxylin & Eosin Stain Kit (H-3502, Vector Laboratories) according to the
746 manufacturer's instructions. The slides were then scanned with VS200 Slide Scanner
747 (Olympus).

748

749 **Indirect immunofluorescence antibody assay (IFA)**

750 IFA was carried out as previously described [9]. Primary antibodies included
751 CoraLite® Plus 647-conjugated smooth muscle actin (1:200, Proteintech, CL647-
752 67735), CoraLite® Plus 488-conjugated Collagen Type I (1:100, Proteintech, CL488-
753 67288), IL6R α (1:500, Proteintech, 23457-1-AP), p-STAT3 (Tyr705) (1 to 20, Invitrogen,

754 710093), p-SMAD2/3 (p-SMAD2-S465/467 and p-SMAD3-S423/425, 1:500, ABclonal,
755 AP0548), and TGF- β RII (1:10, R&D Systems, AF-241-NA). Secondary antibodies
756 included Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa
757 Fluor™ Plus 555 (1:400, Invitrogen, A32732), Donkey anti-Mouse IgG (H+L) Highly
758 Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 568 (1:400, Invitrogen, A10037).

759

760 **Cell segmentation**

761 Reads in a tissue sample were segmented into corresponding cells using the
762 Baysor cell segmentation algorithm [10]. Baysor applies a Markov Random Field model
763 to identify spatial clustering of reads from the same cell. It can perform cell
764 segmentation based on read coordinates alone but can also incorporate nuclear
765 information from DAPI staining. We first utilized the DAPI-stained images of the tissues
766 and performed the nuclei segmentation using the *CellPose* anatomical segmentation
767 algorithm with the default setting of parameters [77]. Segmented nuclei masks with
768 locations were provided to Baysor to define its scale and standard deviation
769 parameters. Baysor was able to segment 71%- 91% of reads after the first run for all
770 samples/tissues. However, we found that among the unsegmented, the so-called noisy
771 background reads determined by Baysor, there is a considerable portion that could still
772 be assigned to cells visually. To address this issue, we applied Baysor again to these
773 noisy reads from the first Baysor run. We optimized the scale and standard deviation
774 parameter for the second Baysor run to maximize reads assignment to cells. Including
775 the second run significantly improved the percentages of the segmented reads to 88%-

776 95% for all samples/tissues (Fig. S3, S4 and Table S2). We implemented only two runs
777 because the remaining unsegmented reads were mostly noisy background reads.

778

779 **Normalization and filtering**

780 Segmented gene reads assigned to cells were then filtered using multiple criteria.
781 First, we removed cells that did not contain reads from any marker genes. Second, we
782 removed cells with total read counts <5 or less than 4 genes with reads. Of the
783 remaining cells, read counts for each gene within a cell were tallied and gene
784 expressions were normalized using the *scTransform* algorithm [11] to further remove
785 biases due to technical variability. The normalized expressions of 220 genes were used
786 for subsequent analysis.

787

788 **Cell typing**

789 We determined the cell type of each cell using an in-house curated list of marker
790 genes for 18 cell types (Table S1). For each cell, we calculated the average expression
791 of marker genes for each of the 18 cell types and then assigned the cell type with the
792 highest average expression to this cell. We further annotated infected cells as those
793 with at least one SARS-CoV-2 read. We used UMAP to visualize the expression pattern
794 of cells associated with the identified cell types in a lower dimension by using the
795 visualization pipeline in the Seurat package [85].

796

797 **Image registration**

798 The DAPI images of tissues that were used as a prior for cell segmentation had
799 translational and rotational differences with their corresponding H&E stained images.
800 For single-cell resolution datasets, small spatial geometric changes in the available raw
801 morphology images could have dramatic differences in downstream analysis for
802 studying the pathology signatures using annotated regions in the H&E image. To
803 mitigate these spatial geometric differences, we registered the DAPI and H&E images
804 by maximizing the phase correlation between both images. Here, we selected the DAPI
805 image as a fixed reference because we used DAPI images as references for reads
806 mapping and cell segmentation. To register both images, the H&E stained image is
807 transformed by changing the scale, rotation, and translation parameters and moved
808 across the DAPI image to improve the phase correlation of both 2D images. Once a
809 peak correlation value was found, the optimization algorithm returned the 2D geometric
810 transformations required to warp the H&E-stained image and registered it to the
811 corresponding DAPI image. We applied the same image registration algorithm to all six
812 samples used in this study. Pathology annotations were carried out on the registered
813 H&E images.

814

815 **Cell density analysis**

816 The abundance of cells relative to the tissue context could reveal biology related
817 to cell proliferation, cell damage, as well as other pathologies related to infection. In our
818 spatial analysis pipeline (Fig. 1B), we defined cell density based on the number of cells
819 within a neighborhood of a fixed radius of 200 units ($200 \times 0.32 \mu\text{m}/\text{unit} = 64 \mu\text{m}$)
820 centering a cell, covering an area of 0.013 mm^2 . By calculating the number of cells

821 within the fixed neighborhoods of each cell, we summarized the global cell density
822 patterns across the tissue. We further presented the cell density as a contour plot by
823 fitting a 2D kernel density estimator (KDE) on the cell density feature (Fig. 3).

824

825 **Neighboring cell type composition analysis**

826 Local cell type distributions can reveal tissue structures and different COVID-19
827 pathology. We assessed the local cell type distribution by computing the neighboring
828 cell type composition (NCTC) of each cell. NCTC defined a cellular neighborhood of 200
829 cells and counts the number of different cell types in the neighborhood to create a
830 neighborhood count vector for each cell. This neighborhood count vector was
831 normalized to obtain the percentages of cell types. NCTC summarized the distributions
832 of each cell type in the vicinity of a cell and was further used to analyze the spatial
833 correlation of different cell types in a region-of-interest (ROI), study spatial gene
834 expression patterns of local neighborhoods, identify local hotspots of individual cell
835 types, and more. Furthermore, the neighborhood composition of individual cell types is
836 spatially mapped by painting the neighborhood count/percentage of the selected cell
837 type with a continuous “rainbow” color scheme where deeper violet to deeper reds
838 indicates a range of low-to-high neighborhood cell composition (Fig. S10-S15).

839

840 **Spatial gene expression map**

841 SSCT captures gene expression of single cells in the context of intact tissue
842 structures. In our study, we investigated the spatial organization of cells in tissue and
843 their gene expression by studying their spatial gene expression maps (SGM). For each

844 gene, its SGM is defined as the sum of the expression of that gene in its 200 nearest
845 neighboring cells. Thus, SGM represents a spatial gradient by summarizing the regions
846 with high or low gene expression patterns. We then painted the SGM using the
847 continuous rainbow colormap similar to the NCTC analysis, generating the spatial gene
848 expression maps illustrated in Fig. 2B, 2C, and 4F. By comparing the SGM with
849 available pathology annotations, pathology signatures with relevant expression patterns
850 can be localized to specific spatial regions in the tissue. Additionally, novel pathology
851 signatures or ROIs can be discovered using the proposed SGM analysis.

852

853 **Local infection rate analysis**

854 We used the local infection rate analysis to study the spatial distribution of
855 SARS-Cov-2 infection. It was similar to the NCTC analysis and computed the
856 percentage of infected cells in a fixed physical area of 1.286 mm² or a radius of 2,000
857 units (640 μm) around each cell across the tissue. These spatial rates can be further
858 visualized using the same rainbow color scheme as NCTC (Fig. 3A).

859

860 **Ligand-receptor coexpression map**

861 Ligand-receptor interactions among cells in a defined location can define spatial
862 patterns of immune microenvironments due to SARS-CoV-2 infection. To infer the
863 interactions, we examine the spatial co-expression between a ligand-receptor pair.
864 Inspired by Moran's I spatial cross-correlation, we computed the spatial coexpression
865 between ligand x and receptor y for cell i as

866
$$E_i = x_i \sum_{j \in \mathcal{N}_i} y_j$$

867 where $x_i = 1$ ($y_j = 1$) if ligand x (receptor y) expressed in cell i (j) and 0, otherwise and
868 \mathcal{N}_i defines a set of neighboring cells of cell i , which are cells within a radius of 1,000
869 units (320 μm) or a fixed physical area of 0.322 mm^2 around cell i . Then, we visualized
870 the coexpression in a tissue using a fixed monochrome color scheme (Fig 3F).

871

872 **Moran's I analysis of spatial patterns**

873 Spatial global autocorrelation of one variable or more variables can be
874 summarized using Moran's I score. However, calculating the global spatial
875 autocorrelation using Moran's I across the whole tissue assumes homogeneity of the
876 studied variable and yields only one statistic that summarizes the complete spatial
877 pattern across the tissue disregarding their difference over space. Since our SARS-
878 CoV-2 infected tissue samples show spatial heterogeneity, in this study, we used Local
879 Indicators of Spatial Association (LISA) [86] to evaluate the spatial autocorrelation and
880 the statistical significance of a study variable in each location using Local Moran's I.

881 Consider x_i as, e.g., the neighboring infection rate of a cell at location i , the
882 univariate spatial autocorrelation can be found as the degree of linear association
883 between x_i and a weighted average of the neighboring cells x_j , based on a spatial
884 weight w_{ij} between cells at location i and j . Thus, formally, Moran's I for each location i
885 is given by

$$886 \quad I_i = \frac{x_i - \bar{x}}{m_2} \sum_{j=1}^N w_{ij} (x_j - \bar{x})$$

887 where N defines the number of cells, \bar{x} defines the mean of all the cells, and m_2 is given
888 by

889
$$m_2 = \frac{\sum_{i=1}^N (x_i - \bar{x})^2}{N}$$

890 I_i ranges from -1 to 1 with -1 indicating highly negative and +1 indicating highly positive
891 spatial autocorrelation. Such formulation can be used to identify spatial regions with
892 high or low autocorrelation. For example, in Fig. 3B, we identified regions with high and
893 low infection rates in each tissue.

894 Under the same formulation, bivariate spatial autocorrelation can be used to
895 assess spatial cross-correlation of a feature x_i , e.g., the neighboring infection rate of a
896 cell at location i and another feature y_j , e.g., the cell density of a neighboring cell j as

897
$$I_i = \frac{x_i - \bar{x}}{m_2} \sum_{j=1}^N w_{ij} (y_j - \bar{y})$$

898 where I_i defines the degree of linear association between the neighboring infection rate
899 of a cell at location i and a weighted average of the cell density of the neighboring cells.
900 Bivariate spatial associations can uncover cross-correlations between any such variable
901 x at location i and another variable y at neighboring locations by ignoring correlations
902 between x and y for cases where $i = j$. In our study, the bivariate LISA method is used
903 to calculate the Local Moran's I to identify HIHD regions described in Fig. 3E.

904

905 **Sparse Non-negative matrix factorization (SNMF) of neighboring cell type** 906 **compositions**

907 SNMF was applied to extract interpretable, tissue-specific, and tissue-
908 independent signatures from NCTC vectors from all tissue samples [63]. Let $\mathbf{A} \in$
909 $(\mathbf{0}, \mathbf{1})^{N \times M}$ represent the NCTC matrix of N cell types and M cells and it is factored as

910

911 $A \approx SDH$

912

913 where $S \in (0, 1)^{N \times K}$ is the matrix of K NCTC signatures with each column denoting a
914 signature, $H \in (0, 1)^{K \times M}$ is the signature loading matrix with m th column denoting the
915 contributions of each signature to the NCTC vector of cell m , and $D \in \mathbb{R}^{K \times K}$ is a scaling
916 matrix.

917 R package *RcppML* was used for the SNMF analysis [63], which implemented
918 an alternating least squares (ALS) algorithm to minimize the mean squared error (MSE)
919 between A and SDH . L_1 regularization was introduced to promote a compact, sparse
920 signature loading.

921 Determining the best number of signatures K is important for uncovering
922 meaningful signatures. While an underestimated number could miss critical signatures,
923 an overestimated number would include many noisy signatures. To this end, we
924 evaluated different maximum numbers of factors from 4 to 12 and examined the
925 meaning regarding its cell type composition and spatial distributions of loadings of each
926 signature and chose $K = 7$ for the SNMF analysis.

927

928 **Trajectory analysis**

929 The goal of trajectory analysis is to infer a progression or ‘pseudotime’ of
930 infection severity and associated tissue damages based on NCTC patterns in all
931 tissues. We applied the trajectory analysis to uncover the pseudotime of 1) infection
932 severity among tissues and 2) tissue damage defined by immune microenvironments.
933 For 1), we used loadings of Signature 1 “Normal-like Alveoli” and Signature 3 “Broad

934 Immune Infiltration” obtained from SNMF and defined tissue samples as clusters. For
935 2), we used the loadings of Signature 1 and four immune microenvironment-related
936 signatures, *i.e.*, Signature 4-7, and performed Louvain clustering to define the clusters.
937 The R package *Slingshot* was used to infer the trajectory [64]. The loadings, clusters,
938 and the signatures or the 2-D UMAP matrix were fed into *Slingshot* to obtain so-called
939 ‘pseudotime’ scores for each cell. For both cases, the cluster enriched by cells from the
940 non-infected tissue (PBC-PR) cells was set as the origin.

941 The pseudotime scores of the cells in each trajectory can correlate with gene
942 expression to uncover genes that correlate with tissue damage. Additionally, ligand-
943 receptor coexpressions that correlate with each trajectory could inform potential ligand-
944 receptor interactions that govern immune responses. To this end, we computed the
945 Spearman correlation of the pseudotime score with the expression of each gene per cell
946 type in each trajectory. We also computed the correlation of ligand-receptor
947 coexpressions with the pseudotime score of each trajectory. In both cases, to properly
948 assess *p-values*, we performed a permutation test to obtain the empirical null
949 distribution of the correlation coefficients and chose *p-value*<0.5 as the significant level.
950 We then plotted heatmaps to illustrate the cell-type-wise correlations of the genes in
951 each trajectory (Fig. S26A-D).

952

953 **Publicly available scRNA-seq datasets**

954 Two scRNA-seq datasets were obtained and processed as follows.

- 955 1. COVID-19 scRNA-seq dataset [4]. The dataset (SCP1052, lung.h5ad.gz) was
956 downloaded from the Single Cell Portal

957 (https://singlecell.broadinstitute.org/single_cell). The processed data file
958 lung.h5ad was accessed using the Python package Scanpy (Scanpy 1.9.1).
959 UMAP coordinates for the processed data were accessed from the file
960 upload.scp.X_umap.coords.txt. No follow-up processing was performed on the
961 processed *anndata* object after it was loaded into Scanpy.

962 2. IPF scRNA-seq dataset [72]. The dataset (GSE135893,
963 GSE135893_ILD_annotated_fullsize.rds.gz) was downloaded from Gene
964 Expression Omnibus (GEO). The Seurat object file was converted into the h5ad
965 file format using the SeuratData package (Seurat 4.3.0, SeuratData 0.2.2). After
966 conversion, the data was loaded in Scanpy (Scanpy 1.9.1) and all cells not
967 originating from an IPF sample or control sample were removed.

968

969 **Statistics and reproducibility**

970 Reads-based cell segmentation was performed using *Baysor* (version 0.5.2).
971 Nuclei segmentation from DAPI images was performed using *CellPose* (version 2.1.1).
972 All other image analyses including imaging registration were performed using MATLAB
973 (version 2022a). Unless otherwise specified, p -value < 0.05 was considered significant.
974 The differential expression analysis was performed in R (version 3.6.3) using the
975 Wilcoxon rank-sum test with Bonferroni's correction of multiple testing as necessary.
976 The Moran's I analyses for spatial patterns were performed using GeoDa (version 1.20).
977 Pearson correlation coefficients were calculated using function *pearsonr* in Python
978 Scipy (version 1.9.3). UMAP dimension reduction and visualization were performed

979 using function *DimPlot* in Seurat (version 4.2.0). Trajectory analyses were performed

980 using R package *Slingshot* (version 2.6.0).

981

982 Reference

- 983 1. Ren, X., et al., *COVID-19 immune features revealed by a large-scale single-cell*
984 *transcriptome atlas*. Cell, 2021. **184**(23): p. 5838.
- 985 2. Melms, J.C., et al., *A molecular single-cell lung atlas of lethal COVID-19*. Nature,
986 2021. **595**(7865): p. 114-119.
- 987 3. Wilk, A.J., et al., *A single-cell atlas of the peripheral immune response in patients*
988 *with severe COVID-19*. Nat Med, 2020. **26**(7): p. 1070-1076.
- 989 4. Delorey, T.M., et al., *COVID-19 tissue atlases reveal SARS-CoV-2 pathology and*
990 *cellular targets*. Nature, 2021. **595**(7865): p. 107-113.
- 991 5. Stephenson, E., et al., *Single-cell multi-omics analysis of the immune response*
992 *in COVID-19*. Nat Med, 2021. **27**(5): p. 904-916.
- 993 6. Erjefalt, J.S., et al., *Diffuse alveolar damage patterns reflect the immunological*
994 *and molecular heterogeneity in fatal COVID-19*. EBioMedicine, 2022. **83**: p.
995 104229.
- 996 7. Asp, M., J. Bergenstrahle, and J. Lundeberg, *Spatially Resolved Transcriptomes-*
997 *Next Generation Tools for Tissue Exploration*. Bioessays, 2020. **42**(10): p.
998 e1900221.
- 999 8. Larsson, L., J. Frisen, and J. Lundeberg, *Spatially resolved transcriptomics adds*
1000 *a new dimension to genomics*. Nat Methods, 2021. **18**(1): p. 15-18.
- 1001 9. Ramos da Silva, S., et al., *Broad Severe Acute Respiratory Syndrome*
1002 *Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal*
1003 *Coronavirus Disease 2019*. J Infect Dis, 2021. **223**(11): p. 1842-1854.
- 1004 10. Petukhov, V., et al., *Cell segmentation in imaging-based spatial transcriptomics*.
1005 Nat Biotechnol, 2022. **40**(3): p. 345-354.
- 1006 11. Hafemeister, C. and R. Satija, *Normalization and variance stabilization of single-*
1007 *cell RNA-seq data using regularized negative binomial regression*. Genome Biol,
1008 2019. **20**(1): p. 296.
- 1009 12. Arish, M., et al., *COVID-19 immunopathology: From acute diseases to chronic*
1010 *sequelae*. J Med Virol, 2022. **95**(1): p. e28122.
- 1011 13. Whitsett, J.A., S.E. Wert, and T.E. Weaver, *Alveolar surfactant homeostasis and*
1012 *the pathogenesis of pulmonary disease*. Annu Rev Med, 2010. **61**: p. 105-19.
- 1013 14. Lin, Z., et al., *Genetic Association of Pulmonary Surfactant Protein Genes,*
1014 *SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis*. Front
1015 Immunol, 2018. **9**: p. 2256.
- 1016 15. Floros, J., et al., *Human Surfactant Protein SP-A1 and SP-A2 Variants*
1017 *Differentially Affect the Alveolar Microenvironment, Surfactant Structure,*
1018 *Regulation and Function of the Alveolar Macrophage, and Animal and Human*
1019 *Survival Under Various Conditions*. Front Immunol, 2021. **12**: p. 681639.
- 1020 16. Mikerov, A.N., et al., *Inhibition of hemagglutination activity of influenza A viruses*
1021 *by SP-A1 and SP-A2 variants expressed in CHO cells*. Med Microbiol Immunol,
1022 2008. **197**(1): p. 9-12.
- 1023 17. Garcia-Laorden, M.I., et al., *The role of mannose-binding lectin in pneumococcal*
1024 *infection*. Eur Respir J, 2013. **41**(1): p. 131-9.

- 1025 18. Sawada, K., et al., *Pulmonary collectins protect macrophages against pore-*
1026 *forming activity of Legionella pneumophila and suppress its intracellular growth.* J
1027 Biol Chem, 2010. **285**(11): p. 8434-43.
- 1028 19. Fassan, M., et al., *Multi-Design Differential Expression Profiling of COVID-19*
1029 *Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory*
1030 *Pathways and SFTPC Impaired Transcription.* Cells, 2022. **11**(6): p. 1011.
- 1031 20. Perkins, T.N., M.L. Donnell, and T.D. Oury, *The axis of the receptor for advanced*
1032 *glycation endproducts in asthma and allergic airway disease.* Allergy, 2021.
1033 **76**(5): p. 1350-1366.
- 1034 21. Yue, Q., et al., *Receptor for Advanced Glycation End Products (RAGE): A Pivotal*
1035 *Hub in Immune Diseases.* Molecules, 2022. **27**(15): p. 4922.
- 1036 22. Koerich, S., et al., *Receptors for Advanced Glycation End Products (RAGE):*
1037 *Promising Targets Aiming at the Treatment of Neurodegenerative Conditions.*
1038 Curr Neuropharmacol, 2022. Sep 22. doi:
1039 10.2174/1570159X20666220922153903. Online ahead of print
- 1040 23. Yamaguchi, K., et al., *Association of the RAGE/RAGE-ligand axis with interstitial*
1041 *lung disease and its acute exacerbation.* Respir Investig, 2022. **60**(4): p. 531-
1042 542.
- 1043 24. Hofmann, M.A., et al., *RAGE mediates a novel proinflammatory axis: a central*
1044 *cell surface receptor for S100/calgranulin polypeptides.* Cell, 1999. **97**(7): p. 889-
1045 901.
- 1046 25. Kapandji, N., et al., *Importance of Lung Epithelial Injury in COVID-19-associated*
1047 *Acute Respiratory Distress Syndrome: Value of Plasma Soluble Receptor for*
1048 *Advanced Glycation End-Products.* Am J Respir Crit Care Med, 2021. **204**(3): p.
1049 359-362.
- 1050 26. Chiappalupi, S., et al., *Hyperactivated RAGE in Comorbidities as a Risk Factor*
1051 *for Severe COVID-19-The Role of RAGE-RAS Crosstalk.* Biomolecules, 2021.
1052 **11**(6): p. 876.
- 1053 27. Zhang, K. and S.H. Phan, *Cytokines and pulmonary fibrosis.* Biol Signals, 1996.
1054 **5**(4): p. 232-9.
- 1055 28. Zhu, Y., et al., *Calcium in Vascular Smooth Muscle Cell Elasticity and Adhesion:*
1056 *Novel Insights Into the Mechanism of Action.* Front Physiol, 2019. **10**: p. 852.
- 1057 29. Ringvold, H.C. and R.A. Khalil, *Protein Kinase C as Regulator of Vascular*
1058 *Smooth Muscle Function and Potential Target in Vascular Disorders.* Adv
1059 Pharmacol, 2017. **78**: p. 203-301.
- 1060 30. Morita, K., et al., *Endothelial claudin: claudin-5/TMVCF constitutes tight junction*
1061 *strands in endothelial cells.* J Cell Biol, 1999. **147**(1): p. 185-94.
- 1062 31. Schlingmann, B., S.A. Molina, and M. Koval, *Claudins: Gatekeepers of lung*
1063 *epithelial function.* Semin Cell Dev Biol, 2015. **42**: p. 47-57.
- 1064 32. Williams, M.R., et al., *Gene expression of endothelial cells due to interleukin-1*
1065 *beta stimulation and neutrophil transmigration.* Endothelium, 2008. **15**(1): p. 73-
1066 84.
- 1067 33. Hashimoto, R., et al., *SARS-CoV-2 disrupts respiratory vascular barriers by*
1068 *suppressing Claudin-5 expression.* Sci Adv, 2022. **8**(38): p. eabo6783.
- 1069 34. Pang, L., et al., *Role of caveolin-1 in human organ function and disease: friend or*
1070 *foe?* Carcinogenesis, 2022. **43**(1): p. 2-11.

- 1071 35. Gokani, S. and L.K. Bhatt, *Caveolin-1: A Promising Therapeutic Target for*
1072 *Diverse Diseases*. *Curr Mol Pharmacol*, 2022. **15**(5): p. 701-715.
- 1073 36. Lagrange, J., et al., *Alpha-2-macroglobulin in hemostasis and thrombosis: An*
1074 *underestimated old double-edged sword*. *J Thromb Haemost*, 2022. **20**(4): p.
1075 806-815.
- 1076 37. Vandooren, J. and Y. Itoh, *Alpha-2-Macroglobulin in Inflammation, Immunity and*
1077 *Infections*. *Front Immunol*, 2021. **12**: p. 803244.
- 1078 38. Mathison, R., J.S. Davison, and A.D. Befus, *Neural regulation of neutrophil*
1079 *involvement in pulmonary inflammation*. *Comp Biochem Physiol C Comp*
1080 *Pharmacol Toxicol*, 1993. **106**(1): p. 39-48.
- 1081 39. Sahu, S.K., et al., *Emerging roles of the complement system in host-pathogen*
1082 *interactions*. *Trends Microbiol*, 2022. **30**(4): p. 390-402.
- 1083 40. Magro, C., et al., *Complement associated microvascular injury and thrombosis in*
1084 *the pathogenesis of severe COVID-19 infection: A report of five cases*. *Transl*
1085 *Res*, 2020. **220**: p. 1-13.
- 1086 41. Mastaglio, S., et al., *The first case of COVID-19 treated with the complement C3*
1087 *inhibitor AMY-101*. *Clin Immunol*, 2020. **215**: p. 108450.
- 1088 42. Afzali, B., et al., *The state of complement in COVID-19*. *Nat Rev Immunol*, 2022.
1089 **22**(2): p. 77-84.
- 1090 43. Freeley, S., et al., *Asparaginyl Endopeptidase (Legumain) Supports Human Th1*
1091 *Induction via Cathepsin L-Mediated Intracellular C3 Activation*. *Front Immunol*,
1092 2018. **9**: p. 2449.
- 1093 44. Zizzo, G., et al., *Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling*.
1094 *Front Immunol*, 2022. **13**: p. 795315.
- 1095 45. Zhao, M.M., et al., *Cathepsin L plays a key role in SARS-CoV-2 infection in*
1096 *humans and humanized mice and is a promising target for new drug*
1097 *development*. *Signal Transduct Target Ther*, 2021. **6**(1): p. 134.
- 1098 46. Trapani, J.A. and M.J. Smyth, *Killing by cytotoxic T cells and natural killer cells:*
1099 *multiple granule serine proteases as initiators of DNA fragmentation*. *Immunol*
1100 *Cell Biol*, 1993. **71 (Pt 3)**: p. 201-8.
- 1101 47. Berezin, V., et al., *Targeting of ECM molecules and their metabolizing enzymes*
1102 *and receptors for the treatment of CNS diseases*. *Prog Brain Res*, 2014. **214**: p.
1103 353-88.
- 1104 48. Pimentel, E., *Colony-stimulating factors*. *Ann Clin Lab Sci*, 1990. **20**(1): p. 36-55.
- 1105 49. Venet, F., et al., *Myeloid cells in sepsis-acquired immunodeficiency*. *Ann N Y*
1106 *Acad Sci*, 2021. **1499**(1): p. 3-17.
- 1107 50. Roussel, L. and D.C. Vinh, *ICOSL in host defense at epithelial barriers: lessons*
1108 *from ICOSLG deficiency*. *Curr Opin Immunol*, 2021. **72**: p. 21-26.
- 1109 51. Panneton, V., et al., *Inducible T-cell co-stimulator: Signaling mechanisms in T*
1110 *follicular helper cells and beyond*. *Immunol Rev*, 2019. **291**(1): p. 91-103.
- 1111 52. Mulcahy, H., et al., *LST1 and NCR3 expression in autoimmune inflammation and*
1112 *in response to IFN-gamma, LPS and microbial infection*. *Immunogenetics*, 2006.
1113 **57**(12): p. 893-903.
- 1114 53. Heidemann, J., et al., *Regulated expression of leukocyte-specific transcript (LST)*
1115 *1 in human intestinal inflammation*. *Inflamm Res*, 2014. **63**(7): p. 513-7.

- 1116 54. Chen, Z., X. Qiu, and J. Gu, *Immunoglobulin expression in non-lymphoid lineage*
1117 *and neoplastic cells*. Am J Pathol, 2009. **174**(4): p. 1139-48.
- 1118 55. Vettermann, C. and M.S. Schlissel, *Allelic exclusion of immunoglobulin genes:*
1119 *models and mechanisms*. Immunol Rev, 2010. **237**(1): p. 22-42.
- 1120 56. Napodano, C., et al., *Mono/polyclonal free light chains as challenging biomarkers*
1121 *for immunological abnormalities*. Adv Clin Chem, 2022. **108**: p. 155-209.
- 1122 57. Godyna, S., M. Diaz-Ricart, and W.S. Argraves, *Fibulin-1 mediates platelet*
1123 *adhesion via a bridge of fibrinogen*. Blood, 1996. **88**(7): p. 2569-77.
- 1124 58. Harikrishnan, K., et al., *Cell Derived Matrix Fibulin-1 Associates With Epidermal*
1125 *Growth Factor Receptor to Inhibit Its Activation, Localization and Function in*
1126 *Lung Cancer Calu-1 Cells*. Front Cell Dev Biol, 2020. **8**: p. 522.
- 1127 59. Jackson, C.B., et al., *Mechanisms of SARS-CoV-2 entry into cells*. Nat Rev Mol
1128 Cell Biol, 2022. **23**(1): p. 3-20.
- 1129 60. Felsenstein, S., et al., *COVID-19: Immunology and treatment options*. Clin
1130 Immunol, 2020. **215**: p. 108448.
- 1131 61. Guizani, I., et al., *SARS-CoV-2 and pathological matrix remodeling mediators*.
1132 Inflamm Res, 2021. **70**(8): p. 847-858.
- 1133 62. Zhang, F., et al., *SARS-CoV-2 pseudovirus infectivity and expression of viral*
1134 *entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from*
1135 *the respiratory, urinary, digestive, reproductive, and immune systems*. J Med
1136 Virol, 2021. **93**(12): p. 6671-6685.
- 1137 63. DeBruine, Z.J., K. Melcher, and T.J. Triche Jr, *Fast and robust non-negative*
1138 *matrix factorization for single-cell experiments*. bioRxiv, 2021: p. 2021.09.
1139 01.458620.
- 1140 64. Street, K., et al., *Slingshot: cell lineage and pseudotime inference for single-cell*
1141 *transcriptomics*. BMC Genomics, 2018. **19**(1): p. 477.
- 1142 65. Sweeney, R.M. and D.F. McAuley, *Acute respiratory distress syndrome*. Lancet,
1143 2016. **388**(10058): p. 2416-2430.
- 1144 66. Wynn, T.A., *Cellular and molecular mechanisms of fibrosis*. J Pathol, 2008.
1145 **214**(2): p. 199-210.
- 1146 67. Turpin, E.A., et al., *Respiratory syncytial virus infection reduces lung*
1147 *inflammation and fibrosis in mice exposed to vanadium pentoxide*. Respir Res,
1148 2010. **11**: p. 20.
- 1149 68. Elewa, Y.H.A., et al., *Histopathological Correlations between Mediastinal Fat-*
1150 *Associated Lymphoid Clusters and the Development of Lung Inflammation and*
1151 *Fibrosis following Bleomycin Administration in Mice*. Front Immunol, 2018. **9**: p.
1152 271.
- 1153 69. Nagata, N., et al., *Features of idiopathic pulmonary fibrosis with organizing*
1154 *pneumonia*. Respiration, 1997. **64**(5): p. 331-5.
- 1155 70. Phan, S.H., *The myofibroblast in pulmonary fibrosis*. Chest, 2002. **122**(6 Suppl):
1156 p. 286S-289S.
- 1157 71. Ortiz-Zapater, E., et al., *Lung Fibrosis and Fibrosis in the Lungs: Is It All about*
1158 *Myofibroblasts?* Biomedicines, 2022. **10**(6).
- 1159 72. Habermann, A.C., et al., *Single-cell RNA sequencing reveals profibrotic roles of*
1160 *distinct epithelial and mesenchymal lineages in pulmonary fibrosis*. Sci Adv,
1161 2020. **6**(28): eaba1972.

- 1162 73. Laloglu, E. and H. Alay, *Role of transforming growth factor-beta 1 and connective*
1163 *tissue growth factor levels in coronavirus disease-2019-related lung Injury: a*
1164 *prospective, observational, cohort study.* Rev Soc Bras Med Trop, 2022. **55**: p.
1165 e06152021.
- 1166 74. Vaz de Paula, C.B., et al., *COVID-19: Immunohistochemical Analysis of TGF-*
1167 *beta Signaling Pathways in Pulmonary Fibrosis.* Int J Mol Sci, 2021. **23**(1): p.
1168 168.
- 1169 75. Fan, T., et al., *Discovery of 9O-Substituted Palmatine Derivatives as a New*
1170 *Class of anti-COL1A1 Agents via Repressing TGF-beta1/Smads and*
1171 *JAK1/STAT3 Pathways.* Molecules, 2020. **25**(4): p.773.
- 1172 76. Malik, M., et al., *Cross-talk between Janus kinase-signal transducer and activator*
1173 *of transcription pathway and transforming growth factor beta pathways and*
1174 *increased collagen1A1 production in uterine leiomyoma cells.* F S Sci, 2020.
1175 **1**(2): p. 206-220.
- 1176 77. Stringer, C., et al., *Cellpose: a generalist algorithm for cellular segmentation.* Nat
1177 Methods, 2021. **18**(1): p. 100-106.
- 1178 78. Qi, F., et al., *Single cell RNA sequencing of 13 human tissues identify cell types*
1179 *and receptors of human coronaviruses.* Biochem Biophys Res Commun, 2020.
1180 **526**(1): p. 135-140.
- 1181 79. Sungnak, W., et al., *SARS-CoV-2 entry factors are highly expressed in nasal*
1182 *epithelial cells together with innate immune genes.* Nat Med, 2020. **26**(5): p. 681-
1183 687.
- 1184 80. Xu, G., et al., *The differential immune responses to COVID-19 in peripheral and*
1185 *lung revealed by single-cell RNA sequencing.* Cell Discov, 2020. **6**: p. 73.
- 1186 81. Zou, X., et al., *Single-cell RNA-seq data analysis on the receptor ACE2*
1187 *expression reveals the potential risk of different human organs vulnerable to*
1188 *2019-nCoV infection.* Front Med, 2020. **14**(2): p. 185-192.
- 1189 82. Sounart, H., et al., *Dual spatially resolved transcriptomics for SARS-CoV-2 host-*
1190 *pathogen colocalization studies in humans.* bioRxiv, 2022: p. 2022.03.
1191 14.484288.
- 1192 83. Pielawski, N., et al., *TissUUmaps 3: Interactive visualization and quality*
1193 *assessment of large-scale spatial omics data.* BioRxiv, 2022. doi:
1194 <https://doi.org/10.1101/2022.01.28.478131>.
- 1195 84. Solorzano, L., G. Partel, and C. Wahlby, *TissUUmaps: interactive visualization of*
1196 *large-scale spatial gene expression and tissue morphology data.* Bioinformatics,
1197 2020. **36**(15): p. 4363-4365.
- 1198 85. Satija, R., et al., *Spatial reconstruction of single-cell gene expression data.* Nat
1199 Biotechnol, 2015. **33**(5): p. 495-502.
- 1200 86. Anselin, L., *Local indicators of spatial association—LISA.* Geographical analysis,
1201 1995. **27**(2): p. 93-115.
1202

1203 **Acknowledgments**

1204 We thank members of Drs. Shou-Jiang Gao and Yufei Huang laboratories for
1205 technical assistance and discussions. This study was supported by grants from the
1206 National Institutes of Health (CA096512 and CA124332 to S.-J. Gao), UPMC Hillman
1207 Cancer Center Startup Funds to S.-J. Gao and Y. Huang, and in part by award
1208 P30CA047904. This research was also supported in part by the University of Pittsburgh
1209 Center for Research Computing, RRID:SCR_022735, through the resources provided.
1210 Specifically, this work used the HTC cluster, which is supported by the National Institutes
1211 of Health (S10OD028483).

1212

1213 **Author contributions**

1214 S.-J. Gao and Y. Huang conceived, designed, supervised and managed the
1215 project. W. Meng, S.R. da Silva and L.P. Chen performed the experiments. G.L. Sica
1216 and W. Meng performed the pathological examination. A. Das, Z.T. Liu, D.M. Hasib, H.
1217 Galloway and Y. Huang developed the computational pipeline and performed the
1218 analyses. A. Das, W. Meng, Z.T. Liu, D.M. Hasib, H. Galloway, S.R. da Silva, L.P.
1219 Chen, Y.F., K.P. Rivera, M. Flores, Y.-C. Chiu, Y. Huang and S.-J. Gao interpreted the
1220 data and participated in the discussions throughout the analysis. A. Paniz-Mondolfi, C.
1221 Bryce, Z. Grimes, E.M. Sodillo and C. Cordon-Cardo obtained the COVID-19 samples.
1222 Y. Huang and S.-J. Gao wrote the manuscript with input from all the authors. All the
1223 authors read, reviewed and approved the manuscript.

1224

1225 **Competing interests**

1226 The authors declare no competing interests.

1227

1228 **Data availability**

1229 The data supporting findings in this study including all the original spatial single-
1230 cell transcriptome data, segmented and filtered reads of all cells, and DAPI and H&E
1231 staining images will be deposited to Zenodo. The spatial single-cell transcriptome data
1232 will also be deposited in GEO.

1233

1234 **Code availability**

1235 All codes will be available at Zenodo.

1236

1237 **Supplementary information**

1238 The online version contains supplementary material available at:

1239

1240 **Correspondence and requests for materials** should be addressed to Shou-Jiang Gao
1241 or Yufei Huang.

1242 **Figure Legend**

1243 **Figure 1: Spatial organization of parenchymal and immune cells in COVID-19 lung**
1244 **tissues revealed by spatial single-cell transcriptome analysis (SSCTA). A.**

1245 Schematic illustration of the spatial single-cell sequencing pipeline used to generate the
1246 target dataset comprised of healthy control (non-COVID-19 tissue, n=1) and COVID-19
1247 tissues (n=5). Samples were hybridized and decoded by sequencing. DAPI and H&E
1248 staining were carried out. All samples were annotated by an expert pathologist (Fig.
1249 S1). **B.** SSCTA workflow illustrating cell segmentation, cell typing, neighborhood cell-
1250 type composition (NCTC) analysis, and tissue pathology analysis. **C.** Average
1251 expression of cell type markers of all segmented cells across identified cell types in the
1252 SSCTA dataset. **D.** The UMAP projection of the gene expressions of segmented cells
1253 colored based on cell type, infection, and sample identifier. The UMAP shows negligible
1254 batch differences between the samples. **E.** Spatial visualization of identified cell types in
1255 two COVID-19 tissues and the non-COVID-19 tissue along with individual spatial plots
1256 illustrating the neighborhood cell type composition of specific cell types. We identified
1257 DAD in all COVID-19 tissues and orderly distribution of major parenchymal cells in non-
1258 COVID-19 tissue (PBC-PR). Further plots are provided in Fig. S1. **F.** Bar plots showing
1259 the percentages of identified cell types and their percentages of SARS-CoV-2 infected
1260 cells.

1261

1262 **Figure 2: SARS-CoV-2 infection induces global differential gene expression that**
1263 **mediates pathological damages and inflammation with cell type and spatial**

1264 **features. A.** Differential gene expressions between the identified cells in the COVID-19

1265 non-COVID-19 tissue with various conditions are illustrated. The title indicates the
1266 conducted differential expression analysis. Within each row, the bubble size indicates
1267 the $-\log_{10}$ of the corrected p-value and the color indicates the \log_2 fold change of the
1268 corresponding gene. Each column indicates the different COVID-19 tissues. The first
1269 three panels indicate differential expression analysis between COVID-19 tissues and
1270 non-COVID-19 tissue while the fourth panel indicates the differential expression
1271 analysis between the infected and uninfected cells in the respective COVID-19 tissues.
1272 **B.** Spatial gene expression map of highly expressed CTSL and IGKC. **C.** Spatial gene
1273 expression maps of the rest of the differentially expressed genes. **D.** Pie chart
1274 illustrating the percentages of cell types in which the genes are expressed in each
1275 tissue. **E.** Differential expression analysis of COVID-19 tissues compared to non-
1276 COVID-19 tissue in cell types that had significant changes in cell numbers based on
1277 Fig. 1F.

1278
1279 **Figure 3: Spatial analysis of local SARS-CoV-2 infection rates identifies regions**
1280 **with high infection rates that match high cell densities, high levels of viral entry-**
1281 **related factors, and localized pathology.** **A.** Spatial distribution of the SARS-CoV-2
1282 infected cells. The spatial visualization of the infection rates revealed infection hotspots
1283 in the COVID-19 tissues. **B.** Moran's I analysis of spatial patterns revealed spatially
1284 distinct high and low infection regions in each COVID-19 tissue. **C.** Spatial visualization
1285 of the significant local regions identified by Bivariate Moran's I analysis, in which
1286 infection rates and the expressions of TMPRSS2, NRP1, FURIN and ACE2 are spatially
1287 correlated. **D.** Spatial visualization of the kernel density plot for the cell densities

1288 revealed highly dense cellular hotspots in the COVID-19 samples. **E.** Spatial
1289 visualization of the significant local regions identified by Bivariate Moran's I analysis, in
1290 which cell densities and the infection regions are spatially correlated, identified as high-
1291 density high-infection (HIHD) regions. **F.** Spatial visualization of the ligand-receptor
1292 coexpression maps for the CSF3-CSF3R pair, which are highly expressed in the high
1293 infection regions. **G.** Spatial visualization of the significant local regions identified by
1294 Bivariate Moran's I analysis, in which both high infection and high CSF3-CSF3R
1295 coexpression regions are spatially correlated.

1296

1297 **Figure 4: Spatial analysis reveals cellular and gene expression features in regions**
1298 **with high SARS-CoV-2 infection rates. A.** A bar plot showing the cell type
1299 composition of all identified cell types in the high and low infection regions. The increase
1300 in alveolar cells (ACs) might suggest the proliferation of ACs due to injury repair of
1301 alveoli and alveoli capillaries and a decrease in epithelial cells (ECs) and vascular
1302 endothelial cells (VECs) might suggest the damages caused by the infection. **B.** UMAP
1303 projection of the NCTC analysis results of high infection regions (refer to figure 3B)
1304 revealed three distinct clusters out of which two were distinctly enriched in local
1305 compositions of ACs and fibroblasts, which are illustrated on the right with their spatial
1306 visualizations. **C.** Spatial visualization of the compositions in high infection regions
1307 revealed negative correlation of fibroblasts and ACs (-0.6, Pearson correlation) which
1308 overlapped with annotated OP regions (high fibroblasts, low ACs). **D.** Differential
1309 expressions of high and low infection regions of the COVID-19 tissues compared to the
1310 non-COVID-19 tissue, which share 18 of the 20 differentially expressed genes,

1311 confirming strong indirect effect of SARS-CoV-2 infection. **E.** Differential expressions
1312 between the high and low infection regions of the COVID-19 tissues revealed distinct
1313 differentially expressed genes showing upregulation of AC markers SFTPA1 and
1314 SFTPA2 in tissues 1, 3, and 5, and fibroblast markers COL1A1 or COL1A2 in all
1315 COVID-19 tissues. **F.** Spatial visualization of the spatial gene expression map of
1316 COL1A1 and COL1A2 markers.

1317

1318 **Figure 5: Sparse non-negative matrix factorization (SNMF) identifies seven cell**
1319 **composition signatures that recapitulate different healthy and disease statuses.**

1320 **A.** SNMF revealed seven NCTC signatures which are illustrated in a logo plot. **B.**

1321 Spatial NCTC signatures visualized after factor loading for each tissue revealed their
1322 associations with normal structures and broad and tissue-specific infection. **C.**

1323 Trajectory analysis of the cell type compositions with Signatures 1 and 3 generated a
1324 trajectory of reduced normal alveoli and increased immune infiltration from the non-
1325 COVID-19 tissue to COVID-19 tissues 1, 4, 3, 5, and 2. The trajectory agrees with the
1326 order of the severity of pathology in the tissues identified in the H&E stained images
1327 (Fig. S1).

1328

1329 **Figure 6: Unique cell composition signatures define two separate pathological**

1330 **trajectories. A.** The UMAP projection of the Signatures 1 (for non-COVID-19 tissue

1331 reference) and Signatures 4-7 recapitulated the severity of pathological progression

1332 identified in figure 5C. Two trajectories were derived from the pseudo-progressions of

1333 cells defined by these signatures. The trajectories showed a common shared onset T1

1334 and T2 which traverses through Signature 1 “normal-like-alveoli” and Signature 4 “ACs
1335 with MMs infiltration” in T1 and then those enriched by Signature 4 and Signature 5
1336 “VECs with MMs infiltration” in T2. The trajectory then diverged into two paths T3a and
1337 T4a, and T3b and T4b. Path/Trajectory A defined by T3a and T4a progressed through
1338 cells mostly from tissues 3 and 4 enriched in Signature 5 “VEC with MMs infiltration”
1339 ending in Signature 6 “VEC with NK cell infiltration”, which was almost exclusively from
1340 tissue 3. Path/Trajectory B defined by T3b and T4b are enriched by Signature 6 in T3b
1341 and Signature 7 “high fibroblasts with MMs infiltration” in T4b. **B.** UMAP projections of
1342 the five signatures colored based on their individual signature loadings. **C.** Line plots
1343 illustrating the cell type percentages in band T1, T2, T3(a, b), and T4(a, b). **D.** Spatial
1344 visualization of the cells by cell type in each band is shown along with an identified
1345 representative ROI (red box with dotted lines) for each COVID-19 tissue. Column 7
1346 illustrates the H&E morphology image of the COVID-19 tissues with black dotted lines
1347 highlighting the high infection regions. **E.** Zoomed-in images of the ROIs selected are
1348 shown. A close examination revealed characteristics of early DAD in T1 and T2, hyaline
1349 membrane, fibrin, lymphocytic infiltration, collapsed alveoli and capillary structure in T3a
1350 and T4a, and edema, increased fibrin, and organizing pneumonia (OP) in T3b and T4b
1351 suggesting a more advanced stage of DAD.

1352

1353 **Figure 7: IL6-STAT3 and TGF- β -SMAD2/3 pathways mediate COVID-19 lung**
1354 **fibrosis and organizing pneumonia. A.** Zoomed in OP region (bottom, red color
1355 border) and other non-OP regions (top, black color border) from the H&E image of
1356 COVID-19 tissue 1-2C are illustrated. **B.** Identified cells colored based on the cell types

1357 revealed differences in cell composition signatures between OP and other regions. **C.**
1358 Bar plot showing an increase in cell density in OP regions compared to other regions. **D.**
1359 Bar plot showing the percentage of cells per cell type in COVID-19 and non-COVID-19
1360 tissues. There is a decrease in ACs and VECs, and an increase in fibroblasts in the OP
1361 regions of the COVID-19 tissue. An obvious increase in ACs is seen in the non-COVID-
1362 19 sample. **E.** Differential gene expressions between the identified cells in the OP
1363 regions of the COVID-19 tissue sample with cells from the non-COVID-19 tissue and
1364 cells from the other non-OP regions of the same COVID-19 tissue is illustrated. We
1365 observed an upregulation of genes encoding for collagen type I alpha 1 and 2 chains
1366 (COL1A1 and COL1A2) in OP in both tissues compared to the normal tissue or to
1367 regions without OP in the same COVID-19 lung tissues. **F.** Pie chart illustrating the
1368 percentages of cell types in which the selected genes are expressed in tissues 1 and 2.
1369 **G.** Spatial visualization of differentially expressed genes from figure 7E. The size of the
1370 dots indicates the expression level, and the color indicates the cell type of the cell where
1371 the gene is expressed. **H.** Differential gene expressions between the identified cells in
1372 the OP regions of the COVID-19 tissue with cells from the non-COVID-19 tissue as well
1373 as non-OP regions from the same COVID-19 tissue based on their cell types. Both
1374 COL1A1 and COL1A2 were upregulated in fibroblasts in OP regions compared to
1375 fibroblasts from either normal tissue or non-OP regions from the same tissue. **I.** The
1376 density plot of the COL1A1 and COL1A2 expressions in OP and other non-OP regions
1377 in COVID-19 tissue samples 1-2C, 2-1A, and non-COVID-19 tissue is illustrated. **J.**
1378 Examination of the networks associated with the Pulmonary Fibrosis Idiopathic
1379 Signaling Pathways reported by the Ingenuity Pathway Analysis is illustrated. Both IL6-

1380 STAT3 and TGF- β -SMAD2/3 pathways mediate the expression of COL1A1 and
1381 COL1A2. **K.** Multi-color IFA staining revealed that cells with a high COL1A1 expression
1382 level also had high levels of IL6R α , p-STAT3, TGF- β R2 and SMAD2/3, confirming the
1383 activation of these pathways and their potential roles in the upregulation of COL1A1.

1384 **Supplemental Information**

1385

1386 **Supplemental Tables**

1387 **Table S1. Gene annotation, cell type markers, and total cells expressing**

1388 **individual genes and total reads of the individual genes in each lung tissue after**
1389 **segmentation.**

1390

1391 **Table S2. Summary of cell segmentation results.**

1392

1393 **Table S3. Summary of cell typing results and SARS-CoV-2 infection status.**

1394

1395 **Table S4. Global spatial correlations between local SARS-CoV-2 infection rates**
1396 **and cell densities by global Moran's I.**

1397

1398 **Table S5. Cell composition signatures identified by sparse non-negative matrix**
1399 **factorization (SNMF).**

1400

1401 **Table S6. Spearman correlations of pseudotime Trajectory A versus gene**
1402 **expressions.**

1403

1404 **Table S7. Spearman correlations of pseudotime Trajectory B versus gene**
1405 **expressions.**

1406

1407 **Supplementary Figures**

1408

1409 **Supplementary Figure 1:** Hematoxylin and eosin (H&E) stained images of the five
1410 COVID-19 tissues (1-2C, 2-1A, 3-1A, 4-3B, 5-3B) and the non-COVID-19 tissue (PBC-
1411 PR) along with pathology annotations are illustrated. We observe various degrees of
1412 diffuse alveolar damage (DAD) in the COVID-19 tissues. Tissues 1 and 2 (1-2C and 2-
1413 1A) had prominent organizing pneumonia (OP) while edema, hyaline membrane, and
1414 fibrin clot were prominent in tissues 3, 4, and 5 (3-1A, 4-3B, and 5-3B).

1415

1416 **Supplementary Figure 2:** 4',6-diamidino-2-phenylindole (DAPI) staining of all tissues
1417 under study revealed the nuclei location. We used the DAPI-stained images to facilitate
1418 cell nuclei segmentation using the CellPose algorithm.

1419

1420 **Supplementary Figure 3: A.** Bar plot showing the total number of reads and the reads
1421 that are segmented to cells using the Baysor algorithm for all tissues under study. We
1422 segmented ~89%-95% of the reads into cells. **B.** Bar plot showing the total number of
1423 segmented cells and the identified cells with a cell-marker read. A total of 1,719,459
1424 cells were identified across the tissues.

1425

1426 **Supplementary Figure 4:** A representative image showing cell boundary polygons of
1427 the cells segmented using the Baysor algorithm. Baysor used a binary mask of the
1428 DAPI image as a prior to guide the cell segmentation.

1429

1430 **Supplementary Figure 5:** Bar plots showing the distribution of the number of
1431 transcripts (reads) that are segmented to each cell. Over 99% of the cells harbored at
1432 least 5-15 reads.

1433

1434 **Supplementary Figure 6:** Heatmaps illustrating the average expressions of marker
1435 genes in each cell type within each tissue. In all tissues, a total of 18 cell types were
1436 identified including 11 types of parenchymal cells and 7 types of immune cells.

1437

1438 **Supplementary Figure 7:** Uniform Manifold Approximation and Projection (UMAP) of
1439 the gene expressions of individual cells revealed separated clusters for major
1440 parenchymal cells including alveolar cells (ACs) and fibroblasts. By contrast, immune
1441 cells were grouped together and mixed with vascular endothelial cells (VECs) in several
1442 clusters. The poor separation of immune cell types was largely due to highly expressed
1443 Immunoglobulin kappa light chain (IGKC) and Cathepsin L (CTSL) in these cell types,
1444 which is further illustrated in Fig. S8.

1445

1446 **Supplementary Figure 8:** The UMAP of the gene expressions of all segmented and
1447 cell-typed cells across all tissues under study is illustrated in the bottom-right panel.
1448 Here, the color of the dots indicates the tissue samples. The rest of the UMAPs illustrate
1449 the expressions of different genes colored based on their expression in each cell. We
1450 observe that IGKC and CTSL are spread across many clusters, resulting in the poor
1451 separation of immune cell types which are mixed with VECs.

1452

1453 **Supplementary Figure 9:** Spatial visualization of the segmented cells painted based on
1454 their cell types along with the location of the SARS-CoV-2 reads marked with an 'X'.

1455

1456 **Supplementary Figure 10:** The neighborhood cell type composition (NCTC) analysis
1457 for COVID-19 tissue 1-2C is illustrated based on the cell type.

1458

1459 **Supplementary Figure 11:** The neighborhood cell type composition (NCTC) analysis
1460 for COVID-19 tissue 2-1A is illustrated based on the cell type.

1461

1462 **Supplementary Figure 12:** The neighborhood cell type composition (NCTC) analysis
1463 for COVID-19 tissue 3-1A is illustrated based on the cell type.

1464

1465 **Supplementary Figure 13:** The neighborhood cell type composition (NCTC) analysis
1466 for COVID-19 tissue 4-3B is illustrated based on the cell type.

1467

1468 **Supplementary Figure 14:** The neighborhood cell type composition (NCTC) analysis
1469 for COVID-19 tissue 5-3B is illustrated based on the cell type.

1470

1471 **Supplementary Figure 15:** The neighborhood cell type composition (NCTC) analysis
1472 for non-COVID-19 tissue PBC-PR is illustrated based on the cell type.

1473

1474 **Supplementary Figure 16:** Spatial visualization of regions with blood vessels revealed
1475 the lining of VECs along the vessels together with other vessel-associated cells

1476 including ACs, fibroblasts and smooth muscle cells (SMCs). Each dot indicates a cell,
1477 and the color of each dot indicates the cell type.

1478

1479 **Supplementary Figure 17:** Spatial visualization of a representative region with
1480 bronchioles revealed the lining of epithelial cells (ECs), smooth muscle cells (SMCs)
1481 and VECs along the bronchiole together with other bronchiole-associated cells including
1482 ACs and fibroblasts. Each dot indicates a cell, and the color of each dot indicates the
1483 cell type.

1484

1485 **Supplementary Figure 18:** Spatial visualization of the expressions of the 19
1486 dysregulated genes in different cell types and their tissue distributions in COVID-19
1487 tissue 1-2C are illustrated. We observe significant variations in the expression patterns
1488 suggesting their complex involvements in different aspects of SARS-CoV-2 infection
1489 and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
1490 size indicates their expression level.

1491

1492 **Supplementary Figure 19:** Spatial visualization of the expressions of the 19
1493 dysregulated genes in different cell types and their tissue distributions in COVID-19
1494 tissue 2-1A are illustrated. We observe significant variations in the expression patterns
1495 suggesting their complex involvements in different aspects of SARS-CoV-2 infection
1496 and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
1497 size indicates their expression level.

1498

1499 **Supplementary Figure 20:** Spatial visualization of the expressions of the 19
1500 dysregulated genes in different cell types and their tissue distributions in COVID-19
1501 tissue 3-1A are illustrated. We observe significant variations in the expression patterns
1502 suggesting their complex involvements in different aspects of SARS-CoV-2 infection
1503 and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
1504 size indicates their expression level.

1505

1506 **Supplementary Figure 21:** Spatial visualization of the expressions of the 19
1507 dysregulated genes in different cell types and their tissue distributions in COVID-19
1508 tissue 4-3B are illustrated. We observe significant variations in the expression patterns
1509 suggesting their complex involvements in different aspects of SARS-CoV-2 infection
1510 and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
1511 size indicates their expression level.

1512

1513 **Supplementary Figure 22:** Spatial visualization of the expressions of the 19
1514 dysregulated genes in different cell types and their tissue distributions in COVID-19
1515 tissue 5-3B are illustrated. We observe significant variations in the expression patterns
1516 suggesting their complex involvements in different aspects of SARS-CoV-2 infection
1517 and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
1518 size indicates their expression level.

1519

1520 **Supplementary Figure 23:** Spatial visualization of the expressions of the 19
1521 dysregulated genes in different cell types and their tissue distributions in non-COVID-19

1522 tissue PBC-PR are illustrated. We observe significant variations in the expression
1523 patterns suggesting their complex involvements in different aspects of SARS-CoV-2
1524 infection and COVID-19 lung pathology. The color of each dot indicates the cell type,
1525 and the size indicates their expression level.

1526

1527 **Supplementary Figure 24:** Bubble plots of cell-type specific differential expression
1528 analysis of the high infection versus the low infection regions of the same COVID-19
1529 tissues is illustrated. The analysis further confirmed the upregulation of SFTPA1 or
1530 SFTPA2 in ACs and COL1A2 in fibroblasts in infected tissues. Within each row, the
1531 bubble size indicates the $-\log_{10}$ of the corrected p-value and the color indicates the \log_2
1532 fold change of the corresponding gene.

1533

1534 **Supplementary Figure 25:** Box plots of signature loadings for each identified signature
1535 generated by the SNMF decomposition of NCTC vectors are illustrated.

1536

1537 **Supplementary Figure 26: A.** Heatmap illustrating the Spearman correlation of the
1538 pseudotime scores of Trajectory A and the gene expression. **B.** Heatmap illustrating the
1539 Spearman correlation of the pseudotime scores of Trajectory B and the gene
1540 expression. **C.** Heatmap illustrating the Spearman correlation of the pseudotime scores
1541 of Trajectory A and the ligand-receptor co-expression values of each cell. **D.** Heatmap
1542 illustrating the Spearman correlation of the pseudotime scores of Trajectory B and the
1543 ligand-receptor co-expression values of each cell. In all plots, deeper red indicates a
1544 high positive correlation and deeper blue indicates a high negative correlation. We also

1545 apply a p-value threshold (p-values<0.5) to remove the genes with lesser correlations
1546 and the removed genes are painted white to indicate no correlation.

1547

1548 **Supplementary Figure 27: Analysis of COVID-19 and IPF single-cell RNA-seq**

1549 **datasets. A.** UMAP projections showing expression of COL1A1 and COL1A2, paired

1550 with fibroblast and myofibroblast cell subtypes from single-cell RNA-seq COVID-19

1551 tissue atlas. Violin plots showing expression of COL1A1 and COL1A2 in cells from

1552 COVID-19 patients. **B.** GSEA enrichment of myofibroblasts in cells ranked by

1553 expressions of COL1A1 and COL1A2 from the single-cell COVID-19 tissue atlas with a

1554 resulting p-value < 0.001. The significant enrichment and the large number of highly

1555 ranked hits indicate that most myofibroblasts from the single-cell COVID-19 tissue atlas

1556 have high expressions of COL1A1 and COL1A2. **C.** UMAP projections showing

1557 expressions of COL1A1 and COL1A2 next to UMAP of fibroblast cell subtypes from

1558 single-cell RNA-seq pulmonary fibrosis dataset. Violin plots showing expressions of

1559 COL1A1 and COL1A2 in IPF and control patients. The UMAPs and violin plots only

1560 represent cells from IPF patients or control. **D.** GSEA enrichment of myofibroblast in

1561 cells from IPF and control donors ranked by expressions of COL1A1 and COL1A2 with

1562 a resulting p-value < 0.001. The significant enrichment and high correlation between the

1563 myofibroblast cell type and high expressions of COL1A1 and COL1A2 indicate that

1564 most myofibroblasts from the single-cell pulmonary fibrosis dataset have high

1565 expressions of COL1A1 and COL1A2. **E.** A heatmap showing expressions of

1566 significantly differentially expressed genes from the 'IPF High' run in cells with high and

1567 low expressions of COL1A1 and COL1A2. **F.** A heatmap showing expressions of

1568 significantly differentially expressed genes from the 'IPF Diagnosis' cells with high and
1569 low expressions of COL1A1 and COL1A2. **G.** GSEA enrichment of significantly
1570 differentially expressed genes from the 'IPF Diagnosis' run against significantly
1571 differentially expressed genes ordered by fold change from the 'IPF High' run with a
1572 resulting p-value < 0.001. The high enrichment of upregulated genes and
1573 downregulated genes from the 'IPF Diagnosis' run in the 'IPF High' run indicates that
1574 the two differential expression analyses are capturing similar expression patterns. **H.** A
1575 heatmap showing expression of differentially expressed genes in cells with high and low
1576 COL1A1 and COL1A2 expressions from the single-cell COVID-19 dataset. **I.** GSEA
1577 enrichment of significantly differentially expressed genes from the 'IPF High' run in
1578 significantly differentially expressed genes from the COVID-19 dataset with a resulting
1579 p-value < 0.001. The high ranking of the 'IPF High' genes indicates that similar genes
1580 co-express with COL1A1 and COL1A2 in both COVID-19 and IPF when considering
1581 IPF and control samples. **J.** GSEA enrichment of differentially expressed genes from
1582 'IPF Diagnosis' against differentially expressed genes from the 'COVID High' run
1583 ordered by fold change with a resulting p-value < 0.001. The high ranking of the 'IPF
1584 Diagnosis' genes indicates that the genes that co-express with COL1A1 and COL1A2 in
1585 COVID-19 have similar co-expression patterns in IPF. **K.** Top 10 enriched pathways
1586 from IPA pathway analysis for the differentially expressed genes from the COVID-19
1587 single-cell RNA-seq dataset.

Figure 1






Figure 2




Figure 3





Figure 4








Figure 6




Figure 7




Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6




Figure S7




Figure S8



Figure S9




Figure S10 - Sample 1-2C Spatial Map of Cell Types




Figure S11 - Sample 2-1A Spatial Map of Cell Types




Figure S12 - Sample 3-1A Spatial Map of Cell Types




Figure S13 - Sample 4-3B Spatial Map of Cell Types




Figure S14 - Sample 5-3B Spatial Map of Cell Types




Figure S15 - Sample PBC-PR Spatial Map of Cell Types




Figure S16




Figure S17




Figure S18: 1-2C




Figure S19: 2-1A




Figure S20: 3-1A




Figure S21: 4-3B




Figure S22: 5-3B




Figure S23: PBC-PR




Figure S24




Figure S25




Figure S26




Figure S27




Table S1. Gene annotation, cell type markers, and total cells expressing individual genes and total reads of the individual genes in each lung tissue after segment

Gene	HGNC ID	Name	Sample name	1-2C		2-1A		3-1A		4-3B		5-3B		PBC-PR	
				Total	Ci	Total	Ci	Total	Ci	Total	Ci	Total	Ci	Total	Ci
A2M	HGNC:7	alpha-2-macroglobulin		42643	80341	28959	37365	9830	11626	24699	33682	74687	1E+05	50795	83748
ACE2	HGNC:1355	angiotensin I converting enzyme 2		213	221	2281	2344	1274	1310	667	694	3353	3471	176	178
ACKR	HGNC:4035	atypical chemokine receptor 1 (Duffy blood g	Vascular endothelial ce	1283	1366	5750	5926	3307	3428	2622	2729	9958	10555	2301	2614
ACTA	HGNC:130	actin alpha 2, smooth muscle	Smooth muscle cells	5164	6156	9006	9442	4110	4296	6756	7571	20041	23428	14003	16904
AGER	HGNC:320	advanced glycosylation end-product specific	Alveolar cells	16263	27549	10958	11939	4034	4371	16636	25020	10146	11282	17701	22204
AGRP	HGNC:330	agouti related neuropeptide		406	427	2963	3067	1601	1655	1154	1208	5717	5966	499	523
AIRE	HGNC:360	autoimmune regulator		196	200	1116	1130	660	671	549	566	1506	1539	321	333
AP1S	HGNC:560	adaptor related protein complex 1 subunit sigma 2		926	962	1135	1166	806	832	591	609	2509	2570	1924	2042
APOE	HGNC:613	apolipoprotein E		12592	17576	21172	27036	6671	7410	22642	32501	7374	7863	5771	6545
ARG1	HGNC:663	arginase 1	Macrophages and mon	385	399	5884	6076	1952	2018	1534	1594	5139	5357	322	332
ASCL1	HGNC:738	achaete-scute family bHLH transcription factor	Epithelial cells	404	418	3640	3738	1531	1583	1713	1793	3938	4080	301	308
ASCL3	HGNC:740	achaete-scute family bHLH transcription factor	Ionocytes	320	333	1475	1544	1194	1254	588	604	1717	1768	203	217
BATF3	HGNC:2891	basic leucine zipper ATF-like transcription factor 3		541	553	2619	2671	1098	1118	983	1013	2611	2673	437	446
BP1FB	HGNC:1610	BPI fold containing family B member 1	Epithelial cells	94	98	333	352	337	348	196	216	1188	1296	81	83
C1QA	HGNC:1241	complement C1q A chain	Macrophages and mon	20720	27989	37792	45071	17616	20129	20676	24133	36007	40708	6548	7757
C1QB	HGNC:1242	complement C1q B chain	Macrophages and mon	12297	14766	51493	58737	17542	19111	18151	20123	47053	53019	5310	5947
C2	HGNC:1248	complement C2		738	783	896	927	497	515	548	576	1156	1211	291	305
C3	HGNC:1318	complement C3		5183	6047	3892	4086	1834	2012	2738	2956	4882	5191	2884	3135
C4BP	HGNC:1325	complement component 4 binding protein alpha		382	402	1406	1452	650	668	475	487	1589	1642	704	735
CAV1	HGNC:1527	caveolin 1		3742	3999	1940	2007	1098	1129	1671	1737	5318	5526	11368	12788
CCL1	HGNC:1061	C-C motif chemokine ligand 17		249	261	1159	1246	1024	1083	424	447	1566	1683	300	311
CCL2	HGNC:1061	C-C motif chemokine ligand 2		1131	1237	4239	4377	1970	2072	589	615	11301	12757	1651	1759
CCL5	HGNC:1063	C-C motif chemokine ligand 5		758	795	938	961	995	1024	537	554	1338	1396	493	510
CCL8	HGNC:1063	C-C motif chemokine ligand 8		254	270	1143	1161	578	595	403	417	2857	3001	146	149
CCR2	HGNC:1603	C-C motif chemokine receptor 2		2594	2753	19388	20595	8426	8872	7505	7945	29142	31621	3473	3643
CCR4	HGNC:1605	C-C motif chemokine receptor 4		408	425	4728	4880	2670	2808	1730	1809	6289	6509	491	507
CCR5	HGNC:1606	C-C motif chemokine receptor 5		1710	1785	12777	13338	4988	5223	4221	4416	15676	16525	1685	1767
CCR6	HGNC:1607	C-C motif chemokine receptor 6		136	142	1197	1219	661	682	428	442	1195	1223	206	212
CCR7	HGNC:1608	C-C motif chemokine receptor 7		577	597	2161	2210	1791	1853	630	654	3593	3686	565	579
CD14	HGNC:1628	CD14 molecule	Macrophages and mon	1773	1852	1668	1700	1539	1575	759	782	2163	2197	498	514
CD16	HGNC:1631	CD163 molecule	Macrophages and mon	2316	2483	6400	6949	3026	3275	3698	4010	9813	10817	1383	1488
CD19	HGNC:1633	CD19 molecule	B cells	761	785	10762	11125	3179	3273	3477	3608	8204	8483	576	590
CD1C	HGNC:1636	CD1c molecule	Dendritic cells	3239	3373	4063	4182	3639	3760	3177	3294	3550	3629	1215	1249
CD20	HGNC:1641	CD209 molecule		384	401	1780	1826	1131	1172	717	736	2537	2620	399	410
GYPE	HGNC:4702	glycophorin A (MNS blood group)	Erythrocyte	161	169	2335	2409	1410	1447	462	477	3642	3775	101	102
CD27	HGNC:1763	CD274 molecule		237	241	1010	1023	498	505	413	429	1149	1175	192	198
CD28	HGNC:1653	CD28 molecule		257	266	2219	2310	1178	1238	792	821	2634	2731	287	297
CD30	HGNC:2887	CD300e molecule		266	269	942	969	639	654	713	733	1574	1612	191	200
CD34	HGNC:1662	CD34 molecule	Vascular endothelial ce	3195	3371	4713	4856	2423	2511	2047	2132	5684	5884	5157	5513
CD3D	HGNC:1673	CD3d molecule	T cells	1154	1216	5081	5261	3234	3360	2383	2496	8192	8618	1223	1282
CD3E	HGNC:1674	CD3e molecule	T cells	451	464	1159	1177	860	879	383	388	1567	1599	603	618
CD3G	HGNC:1675	CD3g molecule	T cells	44	44	109	109	16	16	17	17	54	54	61	61
CD4	HGNC:1678	CD4 molecule	T cells	9244	9854	32619	34880	15017	15908	15346	16465	45532	50512	6899	7329
CD40	HGNC:1191	CD40 molecule		1284	1323	6802	7021	2935	3042	2489	2584	9651	10041	1100	1128
CD40	HGNC:1193	CD40 ligand		785	827	12160	12659	6193	6460	3159	3307	25458	27608	633	663
CD44	HGNC:1681	CD44 molecule (Indian blood group)		3032	3218	4303	4473	2278	2369	2170	2271	12624	13517	5280	5692
CD68	HGNC:1693	CD68 molecule	Macrophages and mon	6117	6731	15311	16792	12141	13295	8779	9502	27401	30488	6359	7170
CD7	HGNC:1695	CD7 molecule		645	676	4375	4464	1954	2005	1387	1432	3516	3618	455	470
CD79	HGNC:1698	CD79a molecule	B cells	1664	1762	21479	22599	6222	6448	4727	4911	15235	15962	800	842
CD79	HGNC:1699	CD79b molecule	B cells	1428	1506	4402	4647	3115	3286	2752	2877	6391	6771	1968	2061
CD80	HGNC:1700	CD80 molecule		653	676	3873	3981	3291	3383	1595	1652	5186	5335	514	534
CD83	HGNC:1703	CD83 molecule		562	588	3093	3184	1163	1202	1034	1077	3142	3256	666	692
CD86	HGNC:1705	CD86 molecule		1	1	6	6	5	5	6	6	7	7	4	4
CD8A	HGNC:1706	CD8a molecule	T cells	690	717	3340	3433	2467	2550	943	971	3632	3738	515	534
CD8B	HGNC:1707	CD8b molecule	T cells	177	182	638	653	684	710	236	247	762	788	173	182
CEAC	HGNC:1820	CEA cell adhesion molecule 8	Granulocytes	592	623	12368	12895	5524	5723	2825	2937	15840	16754	477	493
CFP	HGNC:8864	complement factor properdin		249	259	866	886	522	537	253	259	836	857	168	172
CFTR	HGNC:1884	CF transmembrane conductance regulator	Ionocytes	76	78	664	685	362	372	315	318	935	948	88	92
CLDN	HGNC:2047	claudin 5	Vascular endothelial ce	46145	58039	81977	95546	76968	95416	49549	59676	86131	1E+05	38423	49829
CLEC1	HGNC:1691	C-type lectin domain containing 10A		1432	1507	13952	14589	8036	8443	4628	4847	18709	19859	1189	1257
CLEC5	HGNC:2054	C-type lectin domain containing 5A		155	164	606	618	561	567	330	338	1186	1225	249	255
CLEC7	HGNC:2670	C-type lectin domain containing 9A	Dendritic cells	87	89	1244	1337	761	796	326	337	1788	1901	132	139
COL1	HGNC:2197	collagen type I alpha 1 chain	Fibroblasts	7620	10687	21508	31708	4084	4627	2387	2792	25152	32237	4447	4884
COL1	HGNC:2198	collagen type I alpha 2 chain	Fibroblasts	17445	26898	37213	55927	7678	8625	9522	11572	48486	64941	20266	24613
COL6	HGNC:2211	collagen type VI alpha 1 chain		4358	4725	6794	7095	4101	4285	4035	4278	15730	16919	4344	4608
CPA3	HGNC:2298	carboxypeptidase A3	Granulocytes	172	184	784	830	528	540	334	352	1152	1190	536	568
CR1	HGNC:2334	complement C3b/C4b receptor 1 (Knops blood group)		149	156	535	551	552	567	266	273	924	960	177	183
CSF3F	HGNC:2439	colony stimulating factor 3 receptor		1207	1255	4135	4515	2462	2652	2288	2417	5857	6299	978	1027
CTSB	HGNC:2527	cathepsin B		7288	8303	13176	14716	6499	7033	9760	11249	19731	22099	6933	7722
CTSL	HGNC:2537	Cathepsin L		88357	2E+05	2E+05	4E+05	2E+05	4E+05	1E+05	3E+05	3E+05	6E+05	59979	95863
CX3C	HGNC:2558	C-X3-C motif chemokine receptor 1		2180	2289	4816	4977	5229	5456	3811	3979	6462	6702	2088	2175
CXCL	HGNC:1063	C-X-C motif chemokine ligand 10		503	515	2813	2887	2280	2352	1265	1305	5770	6047		

CXCL1	HGNC:1064	C-X-C motif chemokine ligand 5		115	124	802	821	690	707	380	390	1272	1307	300	318
CXCL1	HGNC:6025	C-X-C motif chemokine ligand 8		584	613	6944	7172	2635	2737	2163	2224	7876	8142	593	612
CXCL1	HGNC:7098	C-X-C motif chemokine ligand 9		910	989	1887	1962	962	994	366	379	2635	2831	1031	1327
CXCR	HGNC:6027	C-X-C motif chemokine receptor 2		384	400	1190	1233	1065	1097	660	680	1723	1785	351	361
CXCR	HGNC:4540	C-X-C motif chemokine receptor 3		1580	1652	13483	14118	7375	7700	3969	4144	15472	16266	1170	1219
CXCR	HGNC:2561	C-X-C motif chemokine receptor 4		409	426	447	453	430	435	363	368	907	927	677	705
CXCR	HGNC:1060	C-X-C motif chemokine receptor 5		1262	1299	22082	23246	6761	6969	4409	4551	26834	28867	608	619
CXCR	HGNC:1664	C-X-C motif chemokine receptor 6		1706	1803	18547	19774	7365	7789	7532	8136	14835	15713	886	911
CYP21	HGNC:2632	cytochrome P450 family 2 subfamily F member 1		126	131	580	585	359	365	233	238	742	755	148	148
DDX5	HGNC:1910	DExD/H-box helicase 58		348	351	970	975	704	723	468	478	2246	2293	398	408
DES	HGNC:2770	desmin	Smooth muscle cells	2105	2251	6468	6681	4351	4512	2619	2745	11073	12074	3562	4077
EDN1	HGNC:3176	endothelin 1		968	1019	1213	1232	810	824	654	682	3617	3760	2183	2341
EOM1	HGNC:3372	eomesoderm		872	913	12299	12803	6617	6955	3231	3372	21051	22484	619	644
EPCAM	HGNC:1152	epithelial cell adhesion molecule	Epithelial cells	473	498	1318	1362	756	781	686	718	1665	1730	566	584
EREG	HGNC:3443	epiregulin		151	152	900	952	696	726	412	435	1556	1636	222	234
F13A	HGNC:3531	coagulation factor XIII A chain		647	686	2258	2430	1186	1244	773	816	2851	3037	467	484
FABP	HGNC:3559	fatty acid binding protein 4		44	46	565	576	347	356	226	232	724	742	241	254
FBLN	HGNC:3600	fibulin 1		13160	18118	12658	14019	3117	3539	7320	8448	19702	22383	11966	14313
FCGR	HGNC:3613	Fc fragment of IgG receptor Ia		136	136	452	455	186	188	82	82	317	320	60	62
FCGR	HGNC:3616	Fc fragment of IgG receptor IIa		920	953	4115	4245	2500	2572	1171	1201	6552	6751	986	1026
FCGR	HGNC:3618	Fc fragment of IgG receptor IIb		499	524	1164	1200	842	858	487	507	1804	1852	442	456
FCGR	HGNC:3620	Fc fragment of IgG receptor IIIb		2732	2890	5795	5991	2908	3009	1843	1929	9812	10392	1547	1656
FKBP	HGNC:1862	FKBP prolyl isomerase 11		1764	1864	10293	10777	10756	11504	4846	5096	20117	21717	1634	1706
FOLR	HGNC:3793	folate receptor beta		1084	1129	1803	1837	1177	1206	792	814	2267	2311	661	679
FOXJ1	HGNC:3815	forkhead box J1	Ionocytes	409	428	3688	3804	1886	1963	1337	1384	4358	4513	343	354
FOXJ1	HGNC:3816	forkhead box J1	Ciliated cells	3	3	3	3	3	3	2	2	18	18		
FOXN	HGNC:2139	forkhead box N4		123	128	489	503	432	437	228	238	624	645	138	141
FOXP	HGNC:6106	forkhead box P3	T cells	2743	2853	24051	25729	6922	7186	4868	5058	13528	14139	2291	2367
FURIN	HGNC:8568	furin, paired basic amino acid cleaving enzyme		2131	2233	10658	11076	4796	4976	5064	5313	14298	14921	2722	2845
FUT4	HGNC:4015	fucosyltransferase 4		969	1012	15533	16926	7541	8103	2887	3034	19700	21747	886	917
GATA	HGNC:4171	GATA binding protein 2	Granulocytes	749	779	3271	3331	1402	1431	832	848	3459	3506	790	812
GATA	HGNC:4172	GATA binding protein 3		339	350	2641	2707	1199	1231	701	713	3269	3374	329	338
CSF3	HGNC:2438	colony stimulating factor 3		6513	7005	56710	64391	16965	18195	14800	15962	39064	43311	4914	5203
GJA5	HGNC:4279	gap junction protein alpha 5		4072	4323	14580	15272	6626	6995	5248	5544	26618	28678	3351	3669
GNLY	HGNC:4414	granulysin		1299	1436	5564	5748	2419	2498	1598	1676	7443	7725	622	671
GPR1	HGNC:3128	G protein-coupled receptor 183		157	159	444	455	547	560	266	276	663	680	238	248
GSTA1	HGNC:4626	glutathione S-transferase alpha 1	Ciliated cells	305	315	1094	1120	949	972	679	702	2015	2069	418	431
GZMK	HGNC:4711	granzyme K		2384	2493	33257	35891	18686	20077	7559	7977	66279	78630	1577	1632
HLA-D	HGNC:4944	major histocompatibility complex, class II, DQ beta 1		1320	1390	1267	1335	790	823	970	1015	1431	1507	1331	1423
HLA-D	HGNC:4954	major histocompatibility complex, class II, DR beta 6 (pseudogene)		769	799	3451	3546	2105	2175	1457	1492	4225	4382	597	621
HPGD	HGNC:1789	hematopoietic prostaglandin D synthase		91	92	470	486	495	514	208	214	673	697	169	172
ICAM	HGNC:5344	intercellular adhesion molecule 1		2515	2710	7157	7385	2243	2313	2848	2976	6938	7172	2268	2381
ICOS	HGNC:5351	inducible T cell costimulator		201	202	1277	1310	586	601	384	401	1182	1213	210	215
ICOSL	HGNC:1708	inducible T cell costimulator ligand		2901	3035	32600	35066	12841	13580	12265	13179	27279	29152	2238	2328
IDO1	HGNC:6059	indoleamine 2,3-dioxygenase 1		640	683	965	986	777	802	637	668	5481	5824	337	361
IFIH1	HGNC:1887	interferon induced with helicase C domain 1		421	434	728	743	433	446	373	380	1621	1670	424	435
IFITM	HGNC:5413	interferon induced transmembrane protein 2		8012	8583	16017	16883	7018	7363	9795	10406	28790	31093	8062	8677
IFITM	HGNC:5414	interferon induced transmembrane protein 3		16452	18575	17428	18617	8998	9577	19021	21300	64561	77842	12481	13753
IFNA2	HGNC:5423	interferon alpha 2		33	33	314	326	281	293	133	135	450	458	58	60
IFNB1	HGNC:5434	interferon beta 1		139	143	1292	1319	641	656	431	453	1382	1421	134	136
IFNE	HGNC:1816	interferon epsilon		54	57	258	264	185	188	98	102	210	219	57	57
IFNG	HGNC:5438	interferon gamma		525	555	4161	4328	3203	3374	1638	1713	5996	6342	357	372
IFNGF	HGNC:5439	interferon gamma receptor 1		1795	1876	1465	1496	724	744	1654	1711	3837	3974	3034	3194
IFNGF	HGNC:5440	interferon gamma receptor 2		713	748	1920	1983	932	959	879	916	3236	3362	1227	1273
IGKC	HGNC:5716	immunoglobulin kappa constant		74828	2E+05	74799	1E+05	55923	1E+05	28740	50571	1E+05	3E+05	12118	15596
IGLL5	HGNC:3847	immunoglobulin lambda like polypeptide 5		2009	2643	7002	7721	4199	4514	3505	3873	11634	13561	1240	1439
IL10	HGNC:5962	interleukin 10		79	81	385	388	209	211	193	199	395	401	72	75
IL10R	HGNC:5965	interleukin 10 receptor subunit beta		833	871	5833	6008	3274	3368	2142	2241	9732	10091	979	1033
IL17A	HGNC:5981	interleukin 17A		378	391	4253	4397	1900	1966	956	979	4913	5080	290	297
IL1A	HGNC:5991	interleukin 1 alpha		488	501	6524	6789	2731	2864	1406	1468	7135	7411	392	403
IL1B	HGNC:5992	interleukin 1 beta		711	735	3369	3432	1390	1419	1180	1226	3375	3448	448	458
IL2	HGNC:6001	interleukin 2		127	131	2079	2133	1121	1190	735	767	2614	2702	159	163
IL22	HGNC:1490	interleukin 22		275	278	3039	3120	1750	1813	1074	1115	3001	3090	232	239
IL27	HGNC:1915	interleukin 27		239	249	2350	2411	924	950	798	819	2139	2190	185	191
IL2RA	HGNC:6008	interleukin 2 receptor subunit alpha		2346	2431	10989	11338	3998	4103	4454	4625	12931	13390	1482	1532
IL33	HGNC:1602	interleukin 33		197	199	394	399	218	221	176	180	620	635	369	384
IL3RA	HGNC:3563	interleukin 3 receptor subunit alpha		946	982	5462	5666	2165	2228	1478	1530	6942	7183	1201	1246
IL4	HGNC:6014	interleukin 4		473	491	3969	4146	1787	1862	1503	1577	3354	3519	319	325
IL5	HGNC:6016	interleukin 5		343	355	1668	1720	964	987	578	592	1304	1355	289	299
IL6	HGNC:6018	interleukin 6		319	333	1430	1471	1062	1094	527	546	4160	4399	1266	1381
IL6R	HGNC:6019	interleukin 6 receptor		554	573	3306	3366	1139	1155	1114	1146	2536	2600	685	717
IL6ST	HGNC:6021	interleukin 6 signal transducer		688	715	1378	1415	632	649	685	709	3566	3700	2331	2450
IL7	HGNC:6023	interleukin 7		287	297	1906	1950	1214	1250	802	827	2714	2797	338	350
IL7R	HGNC:6024	interleukin 7 receptor		3600	3920	4640	4800	1612	1653	2247	2367	3929	4051	2181	2327
INMT	HGNC:6069	indolethylamine N-methyltransferase	Fibroblasts	1312	1396	1323	1387	924	959	1260	1323	3237	3408	5878	6438
IRF4	HGNC:6119	interferon regulatory factor 4		902	921	4295	4375	1593	1623	1110	1134	3447	3509	454	464
ISG15	HGNC:4053	ISG15 ubiquitin like modifier		1784	1866	7142	7480	4105	4337	4103	4309	15226	16219	1369	1443
ITGAX	HGNC:6152	integrin subunit alpha X	Dendritic cells	915	949	1519	1546	1110	1130	1644	1706	2850	2930	730	765
ITLN1	HGNC:1825	intelectin 1		250	259	2774	2848	1509	1544	741	766	3299	3378	248	251

JCHAI	HGNC:5713	joining chain of multimeric IgA and IgM		9916	21499	10626	14866	6728	7953	2628	3794	19176	35488	1454	3375
KIT	HGNC:6342	KIT proto-oncogene, receptor tyrosine kinase		482	499	978	996	730	757	464	480	2147	2212	2120	2278
KLRB	HGNC:6373	killer cell lectin like receptor B1		311	329	1521	1556	888	906	608	625	1945	1995	304	317
KLRC	HGNC:6375	killer cell lectin like receptor C2	NK cells	131	137	484	499	494	502	323	339	675	695	129	133
KLRD	HGNC:6378	killer cell lectin like receptor D1	NK cells	536	562	4258	4482	1868	1931	986	1020	5417	5665	443	456
KRT1	HGNC:6415	keratin 13		184	202	880	902	534	549	396	411	1116	1158	112	113
KRT1	HGNC:6416	keratin 14	Basal cells	265	270	2960	3028	1472	1513	746	768	3546	3641	278	288
KRT1	HGNC:6421	keratin 15		840	901	5259	5485	2733	2867	1606	1684	6785	7147	537	553
KRT1	HGNC:6436	keratin 19		4295	5157	7262	7681	4066	4336	2867	3044	17270	20219	3220	3432
KRT5	HGNC:6442	keratin 5	Basal cells	186	213	589	602	588	705	275	288	3127	4635	112	113
LEF1	HGNC:6551	lymphoid enhancer binding factor 1		214	220	1782	1824	1187	1238	522	544	3048	3185	603	630
LGR6	HGNC:1971	leucine rich repeat containing G protein-coupled receptor 6		499	516	3062	3191	1629	1696	1002	1054	3142	3296	431	448
LILRA	HGNC:1550	leukocyte immunoglobulin like receptor A4		206	210	1596	1636	827	850	568	577	1548	1576	173	176
LST1	HGNC:1418	leukocyte specific transcript 1		5422	5762	68058	78104	25499	27823	13921	14974	72496	84944	4255	4509
LTF	HGNC:6720	lactotransferrin		147	161	1482	1530	767	795	322	332	2419	2485	136	137
LYVE1	HGNC:1468	lymphatic vessel endothelial hyaluronan receptor 1	Lymphatic endothelial	336	352	608	625	308	317	214	221	376	385	740	786
CSF1	HGNC:2432	colony stimulating factor 1		514	528	1226	1251	474	479	314	320	1096	1113	344	348
MGP	HGNC:7060	matrix Gla protein		9428	10545	34860	38829	10408	10997	6878	7373	22754	24270	10835	11935
MKI6	HGNC:7107	marker of proliferation Ki-67		61	62	180	183	191	194	70	71	348	359	59	61
MRC1	HGNC:7228	mannose receptor C-type 1		1143	1197	5250	5446	2179	2227	1635	1693	6191	6375	1428	1522
MS4A	HGNC:7315	membrane spanning 4-domains A1	B cells	132	133	1053	1067	709	725	400	406	1693	1727	110	114
MS4A	HGNC:7316	membrane spanning 4-domains A2	Granulocytes	299	305	3172	3266	1674	1714	833	857	4015	4129	401	414
MSLN	HGNC:7371	mesothelin	Mesothelial cells	1191	1294	3928	4078	1435	1474	913	964	3332	3449	1717	1799
MUC1	HGNC:7508	mucin 1, cell surface associated		955	1021	662	686	638	663	579	609	2614	2738	1132	1189
MUC5	HGNC:7515	mucin 5AC, oligomeric mucus/gel-forming	Epithelial cells	145	158	799	827	453	462	502	528	987	1014	154	157
MUC5	HGNC:7516	mucin 5B, oligomeric mucus/gel-forming	Epithelial cells	1310	1456	14210	14781	7453	7735	4319	4526	24767	26669	853	878
MX1	HGNC:7532	MX dynamin like GTPase 1		1579	1638	7232	7514	2792	2877	3514	3655	11341	11882	1414	1471
NCAN	HGNC:7656	neural cell adhesion molecule 1	NK cells	6110	6557	40906	44692	27697	30467	17120	18732	58792	66620	3296	3515
NKG7	HGNC:7830	natural killer cell granule protein 7		1352	1492	1162	1192	1060	1110	837	875	2043	2111	758	818
NRP1	HGNC:8004	neuropilin 1		4267	4523	4071	4200	2177	2264	2922	3045	11280	11857	4047	4282
PAX5	HGNC:8619	paired box 5		270	277	2099	2158	1711	1760	566	581	3210	3333	253	264
PCSK	HGNC:1730	proprotein convertase subtilisin/kexin type 1 inhibitor		4234	4500	18102	19090	9788	10407	9194	9843	17936	18870	3926	4233
PDCD	HGNC:8760	programmed cell death 1		5017	5317	14253	14860	11119	11612	6214	6484	10882	11277	2413	2483
PECAM1	HGNC:8823	platelet and endothelial cell adhesion molecule	Vascular endothelial ce	538	551	452	458	308	313	527	533	1013	1028	1484	1525
PF4	HGNC:8861	platelet factor 4		271	309	733	751	584	605	393	424	706	729	94	95
PLAC	HGNC:1925	placenta associated 8		1599	1703	9248	9601	4682	4869	2901	3038	12029	12703	1279	1329
PLIN2	HGNC:248	perilipin 2		741	766	5024	5171	2095	2158	1803	1869	7434	7721	939	976
PPAR	HGNC:9236	peroxisome proliferator activated receptor gamma		582	602	4635	4783	2662	2744	1738	1814	7013	7320	1229	1305
PRF1	HGNC:9360	perforin 1		672	690	2647	2784	1522	1595	1416	1495	3888	4107	538	551
PRG4	HGNC:9364	proteoglycan 4	Macrophages and mon	1346	1483	2925	3053	1535	1595	1947	2081	4697	4919	3845	4252
PTN	HGNC:9630	pleiotrophin		2909	3202	7876	8310	4531	4858	4619	5019	8072	8546	2408	2577
PTPR	HGNC:9666	protein tyrosine phosphatase receptor type C		1938	2015	4054	4167	3043	3133	1542	1591	6289	6473	1931	2026
RETN	HGNC:2038	resistin		779	811	7065	7348	3445	3607	2932	3125	9538	10016	715	746
S100	HGNC:1049	S100 calcium binding protein A8		3361	4237	4766	5142	3103	3395	1839	2036	8888	10537	500	553
SCGB	HGNC:1252	secretoglobin family 1A member 1	Epithelial cells	1865	4537	5388	6536	2592	3999	2288	2948	9280	16352	1106	3020
SCGB	HGNC:1839	secretoglobin family 3A member 2	Epithelial cells	534	645	1572	1622	1012	1054	904	988	2634	2825	1687	2580
SEMA	HGNC:1072	semaphorin 3A		72	73	733	749	364	372	245	253	886	914	139	142
SFTA2	HGNC:1838	surfactant associated 2	Alveolar cells	1690	1805	3864	3996	1901	1990	2040	2160	5024	5260	1957	2057
SFTP	HGNC:1079	surfactant protein A1	Alveolar cells	6106	8052	10922	14182	7860	9860	6527	8187	24407	44290	18841	29304
SFTP	HGNC:1079	surfactant protein A2	Alveolar cells	4370	5125	10027	11632	4643	5192	4322	4783	14103	17992	7456	8821
SFTPC	HGNC:1080	surfactant protein C	Alveolar cells	25948	69259	16766	21268	8284	10209	16532	26081	16118	19624	35495	74526
SLC18	HGNC:1093	solute carrier family 18 member A2	Granulocytes	217	223	2954	3056	1801	1871	795	834	4400	4559	291	299
TAGLN	HGNC:1155	transgelin	Smooth muscle cells	345	356	1388	1411	915	931	764	792	1926	1979	1234	1285
TBX2	HGNC:1159	T-box transcription factor 21		1202	1252	5703	5876	3600	3711	2502	2590	7273	7523	971	1004
TGFB1	HGNC:1176	transforming growth factor beta 1		1562	1650	2225	2276	1735	1770	1231	1280	3875	3965	2271	2374
TMPR	HGNC:1187	transmembrane serine protease 2		9404	10363	22628	24172	23341	25544	10743	11645	19259	20485	6563	7089
TNF	HGNC:1189	tumor necrosis factor		151	153	622	634	529	544	186	188	972	987	197	203
TP63	HGNC:1597	tumor protein p63	Basal cells	82	88	413	449	376	401	140	150	549	583	60	61
TPPP	HGNC:2416	tubulin polymerization promoting protein	Ciliated cells	1484	1763	4075	4233	1630	1767	2161	2474	7056	7902	1962	2064
TPSA	HGNC:1201	tryptase alpha/beta 1	Granulocytes	4307	5425	3784	3908	2953	3162	4152	4676	6304	6736	3633	4261
TREM	HGNC:1776	triggering receptor expressed on myeloid cells 2		1367	1428	2553	2640	1472	1517	1370	1424	2609	2673	481	500
TRPM	HGNC:1432	transient receptor potential cation channel subunit 4	Brush cells	298	307	2062	2103	1322	1362	644	665	2399	2467	394	409
TUBB	HGNC:2077	tubulin beta 4B class IVb	Ciliated cells	912	956	599	617	512	524	391	397	1620	1668	982	1009
TYROBP	HGNC:1244	transmembrane immune signaling adaptor		6913	7616	14347	15209	5989	6243	6699	7191	15054	15909	7053	8452
VIM	HGNC:1269	vimentin		930	975	3069	3156	3152	3282	1261	1305	2791	2868	847	873
WT1	HGNC:1279	WT1 transcription factor		62	65	245	246	307	316	138	141	455	460	70	73
IL1R1	HGNC:IL1R1			1780	1867	2331	2400	862	885	1504	1571	11104	11957	2721	2856
CoV	HGNC:			2054	2222	6879	7865	3393	3577	3356	3720	13596	20379		

Table S2. Summary of cell segmentation results

Sample name	1-2C	2-1A	3-1A	4-3B	5-3B	PBC-PR	Total
Total Reads	1,137,704	2,380,636	1,441,118	1,161,277	3,424,675	869,453	10,414,863
Number of Genes	222	222	222	222	222	221	
Total Segmented Reads	1,074,491	2,224,394	1,339,792	1,112,148	3,231,976	773,102	9,755,903
Percentages of Segmented Reads (%)	94.44381	93.43696	92.96893	95.7694	94.37322	88.9182	93
Total Cells	186,659	406,963	276,676	227,585	470,294	151,282	1,719,459
Total Cells with Cell Type Marker Gene	137,260	317,259	193,293	163,431	369,042	126,531	1,306,816
Percentages of Cells with Cell Type Marker Gene (%)	73.53516	77.9577	69.86258	71.81097	78.47049	83.63916	
Total Cells after Filtering	67,701	196,221	87,701	74,843	287,832	62,674	776,972
Average Transcripts per Cell	5.756469	5.465852	4.842476	4.886758	6.87226	5.110371	

Table S3. Summary of cell typing results and SARS-CoV-2 infection status

Sample Name	Alveolar	Macroph	Fibroblast	Vascular	T cells	Granulocyte	B cells	Dendritic	Epithelial	Smooth	NK cells	Ciliated	Ionocyte	Basal cell	Mesothelial	Brush cell	Lymphocyte	Erythrocyte	Total
1-2C Number of Cells	19111	14470	10097	8621	2936	2165	1831	1695	1622	1612	1574	969	275	209	199	142	118	55	67701
Cell Type Percentage(%)	28.229	21.373	14.914	12.734	4.3367	3.1979	2.7045	2.5037	2.3958	2.3811	2.3249	1.4313	0.4062	0.3087	0.2939	0.2097	0.1743	0.0812	100
Number of infected Cells	336	179	152	115	51	32	20	19	30	29	26	23	6	4	2	1	1	0	690
Infected Cell Percentage (%)	1.7581	1.237	1.5054	1.334	1.7371	1.4781	1.0923	1.1209	1.8496	1.799	1.6518	2.3736	2.1818	1.9139	1.005	0.7042	0.8475	0	0.0102
2-1A Number of Cells	28,779	40357	25625	16635	13360	9856	20629	3120	12470	3392	11793	2792	2113	2018	957	1038	222	1065	167442
Cell Type Percentage (%)	14.667	20.567	13.059	8.4777	6.8086	5.0229	10.513	1.59	6.3551	1.7287	6.0101	1.4229	1.0768	1.0284	0.4877	0.529	0.1131	0.5428	100
Number of infected Cells	501	660	350	301	309	210	653	49	228	66	258	56	30	50	14	17	4	15	3771
Infected Cell Percentage (%)	1.7409	1.6354	1.3659	1.8094	2.3129	2.1307	3.1654	1.5705	1.8284	1.9458	2.1877	2.0057	1.4198	2.4777	1.4629	1.6378	1.8018	1.4085	0.0225
3-1A Number of Cells	11,240	16820	4498	15384	5699	4882	6073	2212	5766	1882	8064	1285	1189	1126	332	584	118	547	87,701
Cell Type Percentage (%)	12.816	19.179	5.1288	17.541	6.4982	5.5666	6.9247	2.5222	6.5746	2.1459	9.1949	1.4652	1.3557	1.2839	0.3786	0.6659	0.1345	0.6237	100
Number of infected Cells	363	224	91	276	97	66	131	31	83	43	112	24	17	14	2	8	2	7	1591
Infected Cell Percentage (%)	3.2295	1.3317	2.0231	1.7941	1.7021	1.3519	2.1571	1.4014	1.4395	2.2848	1.3889	1.8677	1.4298	1.2433	0.6024	1.3699	1.6949	1.2797	0.0181
4-3B Number of Cells	17,337	15485	4825	10434	4132	3179	4698	1931	3683	1974	4080	1278	689	459	183	259	60	157	74,843
Cell Type Percentage (%)	23.164	20.69	6.4468	13.941	5.5209	4.2476	6.2771	2.5801	4.921	2.6375	5.4514	1.7076	0.9206	0.6133	0.2445	0.3461	0.0802	0.2098	100
Number of infected Cells	402	267	96	209	94	67	144	32	80	50	90	26	21	9	6	5	3	1	1602
Infected Cell Percentage (%)	2.3187	1.7242	1.9896	2.0031	2.2749	2.1076	3.0651	1.6572	2.1721	2.5329	2.2059	2.0344	3.0479	1.9608	3.2787	1.9305	5	0.6369	0.0214
5-3B Number of Cells	42,922	50411	40691	24428	17326	15181	20224	4651	24242	8788	21432	5747	2828	4558	929	1435	147	1892	#####
Cell Type Percentage (%)	14.912	17.514	14.137	8.4869	6.0195	5.2743	7.0263	1.6159	8.4223	3.0532	7.446	1.9967	0.9825	1.5836	0.3228	0.4986	0.0511	0.6573	100
Number of infected Cells	978	1319	893	768	501	443	524	135	705	258	840	130	89	108	46	33	3	66	7839
Infected Cell Percentage (%)	2.2786	2.6165	2.1946	3.1439	2.8916	2.9181	2.591	2.9026	2.9082	2.9358	3.9194	2.262	3.1471	2.3695	4.9516	2.2997	2.0408	3.4884	0.0272
PBC- Number of Cells	27378	5719	9465	7717	1491	1638	1173	736	1262	3290	629	922	139	159	185	145	199	29	62276
Cell Type Percentage (%)	43.962	9.1833	15.198	12.392	2.3942	2.6302	1.8836	1.1818	2.0265	5.2829	1.01	1.4805	0.2232	0.2553	0.2971	0.2328	0.3195	0.0466	100

Table S4. Global spatial correlations between local SARS-CoV-2 infection rates and cell densities by global Moran's I.

Sample name	1-2C	2-1A	3-1A	4-3B	5-3B
Coefficient (r)	0.325	0.636	0.287	0.248	0.078

Table S5. Cell composition signatures identified by sparse non-negative matrix factorization (SNMF)

	Normal-like Alveoli	Bronchile	Broad immune infiltration	ACs w/MM infiltration	VECs w/MM infiltration	VECs w/NK infiltration	High fibroblasts w/ MM
n-Alveolar	0.5643179	0.0121138	0	0.6477053	0.0404455	0	0.0336691
n-B	0.0177815	0	0.2864881	0.0001489	0.0357681	0.0298888	0.0017179
n-Basal	0	0.1029554	0.0025063	0	0	0.0135613	0
n-Brush	0	0	0.0019199	0	0	0.0032618	0
n-Ciliated	0.0105512	0.1403089	0.002555	0.002187	0.0131246	0	0.0055952
n-Dendritic	0.0076009	0.006494	0.0079063	0.0128054	0.0373424	0.0272293	0
n-Epithelial	0	0.6141461	0.0867002	0.0092846	0	0.1219462	0
n-Erythrocyte	0	0.0014696	0.0023376	0	0	0.0068894	0
n-Fibroblasts	0.1193691	0	0	0	0.031177	0	0.7342991
n-Granulocytes	0.0125711	0.0494878	0.0963014	0.0253557	0.0136434	0.1360229	0.0080645
n-Ionocytes	0	0	0.0145924	0	0.0018038	0.0202377	0
n-Lymphatic	0	0	0	0	0	0	0
n-Macrophages	0	0.0162048	0.2233146	0.2728252	0.4667314	0	0.1577208
n-Mesothelial	0	0	0	0	0	0	0
n-NK	0	0.0066883	0.0999384	0.0296879	0	0.3184191	0.0179067
n-Smooth	0.0529362	0.0501313	0	0	0.0099377	0.0428492	0.0410268
n-T	0.0294544	0	0.17544	0	0.0869477	0.0040867	0
n-Vascular	0.1854178	0	0	0	0.2630784	0.2756075	0

Table S6. Spearman Correlations of Pseudotime Trajectory A versus Gene Expressions

Gene	ACs	VECs	Fibroblasts	MMs	NK cells	T cells	B cells	Granulocytes
A2M	-0.2765578	-0.285168	-0.238348	-0.182516	-0.229521	-0.249141	-0.223907	-0.2508999
ACE2			0.043395			0.061204		
ACTA2	-0.1070443	-0.084294	-0.149374	-0.054684				-0.07261664
AGER	-0.0464048	-0.124302			-0.069421			
AGRP								-0.06517783
AIRE			0.044831					
AP1S2		-0.085735						
APOE		-0.057446		-0.164077	-0.089098	-0.054176	-0.12528	-0.08344893
ARG1			0.046766	0.063714			0.044833	
ASCL1								-0.0473939
BATF3								0.044194834
C1QA				-0.078339				
C1QB	0.0867708		0.059652					0.061753909
C2				-0.045239			-0.042925	
C3		-0.045129			-0.076592	-0.048363	-0.043823	
CAV1	-0.1734009	-0.188403	-0.157273	-0.090972	-0.120304	-0.05613	-0.11769	-0.12119816
CCL17						0.0635		
CCL2					-0.052658			
CCL5						0.04699		
CCR2			0.051705					
CCR5			0.054213					
CCR6								0.045881367
CD163				-0.046732				-0.04655853
CD19	0.0438856							
CD274								-0.04879447
CD28						0.059283		0.046970801
CD34	-0.0782965	-0.120828	-0.099378		-0.071386			
CD3E							0.0501	
CD4			0.046742		-0.046078	-0.086732		
CD40			0.056504		-0.052999			
CD40LG	0.0655237	0.058233	0.046805			0.069183		0.06671726
CD44	-0.0692463	-0.062723		-0.0675			-0.048534	-0.07242388
CD68					0.053609			0.061876787
CD7			0.053738					
CD79A	0.061052							
CD79B							-0.075542	
CD80			0.058972		0.05314			0.074283622
CD8A			0.049234	0.054959		0.070571		0.063172204
CD8B						0.052538		
CEACAM8	0.0634125		0.063658					0.211105625
CFP								0.043873213
CLDN5		-0.080936	-0.055542			-0.065148		-0.0632258
CLEC10A	0.080319	0.050673	0.050981	0.06959		0.070331		

CLEC5A									-0.04331821
COL1A1	-0.0434716		0.095684			-0.044134			
COL1A2	-0.1288032	-0.077353						-0.071241	-0.04643754
COL6A1						-0.051441			
CPA3						-0.04277			-0.05276376
CSF3	0.0825488	0.055434	0.057477						
CTSB				-0.123315	-0.066372	-0.06243		-0.049898	
CTSL	0.1555903	0.134861	0.082006	0.109746		0.064454	0.060173	0.142779746	
CX3CR1								-0.04356	
CXCL16				-0.050227					
CXCL2	-0.0819782	-0.070601	-0.074434		-0.052996	-0.047334		-0.056277	
CXCL5								0.043694	
CXCL9								-0.047127	
CXCR2						0.045496			0.057255351
CXCR3	0.0534724	0.073938	0.07601	0.04483	0.082672				0.091774059
CXCR5	0.0936446	0.055021	0.10011	0.055826			0.073588	0.056048048	
CXCR6	0.0586824		0.093284	0.043907					0.051339988
DES			-0.052901						
EDN1	-0.0567181	-0.047026	-0.05669			-0.053867			-0.0593376
EOMES	0.0643587			0.055331		0.069938			0.046845356
FBLN1	-0.0936202	-0.097959	-0.109604	-0.048301	-0.086736	-0.063898			-0.09633971
FCGR1A								-0.04277	
FCGR3B				-0.04382	-0.047063				0.050848563
FKBP11	0.0833244	0.078857		0.078018	0.069366		0.075718	0.049317294	
FOXI1	0.0456297								0.049750788
FUT4	0.0546642	0.07476	0.050612	0.04718		0.054029			
GATA2								-0.044676	
GJA5					-0.058265				
GYPA								0.055007	
GZMK	0.1124151	0.11247	0.113746	0.090556	0.067483	0.12196	0.077234	0.116377053	
ICOS					0.043273				
ICOSLG	0.0890651	0.080021	0.100679		0.066888				
IDO1					-0.04533				
IFIH1			-0.042804						
IFITM2	-0.0499703	-0.066448				-0.066731	-0.057621	-0.09603561	
IFITM3		-0.111749		-0.052976	-0.138866	-0.102936	-0.07538	-0.12173662	
IFNG	0.0564185	0.048542	0.066231	0.058263					
IFNGR1	-0.068489	-0.075191	-0.072411	-0.046442	-0.063603	-0.043599			-0.07228366
IFNGR2		-0.053552							
IGKC	0.1358517	0.110124	0.130462						
IL10RB						0.043795	0.050399		
IL17A	0.0427097								
IL1A	0.0579209	0.045525	0.048089			0.052517			
IL1B					-0.042758	-0.046179			
IL1R1						-0.045698	-0.066127	-0.04663377	

Table S7. Spearman Correlations of Pseudotime Trajectory B versus Gene Expressions

Gene	ACs	VECs	Fibroblasts	MMs	NK cells	T cells	B cells	Granulocytes
A2M	-0.23417	-0.18242	-0.18695	-0.11699	-0.07008	-0.13915	-0.11668	-0.199064005
ACE2						0.047165		
ACKR1		0.048854					-0.04833	
ACTA2	-0.09122	-0.10498	-0.09113			-0.04457		
AGER	-0.0654	-0.12614	-0.04869					
AGRP	0.049945							
AP1S2	-0.04246	-0.07303					-0.04535	
APOE				-0.07856		-0.03913		
ARG1	0.047952					0.046863		
ASCL1								-0.037819398
BATF3						0.037658		
C1QA	0.058691							0.09027356
C1QB	0.117966	0.054073	0.089102	0.096327			0.058879	0.125662283
C3								-0.063321455
CAV1	-0.15927	-0.18698	-0.14654	-0.07419	-0.07115	-0.05335	-0.04429	-0.103846221
CCL2						0.056462		0.041291612
CCR2	0.06541	0.063104		0.046706		0.038923		0.045579992
CCR4		0.05497	0.03879					
CCR5	0.06756			0.037975	0.051752			
CCR6					0.045262			
CD163								0.037295985
CD19	0.060925	0.040203	0.041826				0.044888	
CD34	-0.0689	-0.09669	-0.06878		-0.0509			
CD4	0.049011							
CD40	0.039212						0.058188	
CD40LG	0.107726	0.077691		0.045761		0.08453		0.068746563
CD44	-0.05332				0.052098			-0.050139472
CD68				-0.07668				
CD7						0.052587		
CD79A	0.08843		0.042754				0.092262	
CD79B							-0.12707	
CD83								0.047211302
CD8A							0.038345	
CEACAM8	0.067966						0.055024	0.214210161
CFTR							0.054296	
CLDN5	-0.0661	-0.08001	-0.08032			-0.1043	-0.05523	-0.079253269
CLEC10A	0.068948	0.065709	0.055969	0.057083		0.074607		
COL1A1			0.238038		0.050449		0.063025	
COL1A2	-0.08054		0.074501				0.060741	-0.043885551
CPA3						-0.0388		-0.058816528
CSF3	0.113034	0.10195	0.072741	0.102288	0.071468		0.088778	0.098683964
CTSB				-0.04035				0.055171045
CTSL	0.104649	0.07678	-0.04173				-0.06617	

CX3CR1					0.043399		-0.04299	
CXCL2	-0.07253	-0.0844	-0.05969	-0.05841	-0.06559	-0.05153	-0.04755	
CXCL5								0.03806835
CXCL9						-0.03978		
CXCR3	0.069483	0.048237			0.037495			0.085780591
CXCR5	0.125108	0.091302	0.039747	0.064412			0.053469	0.056036
CXCR6	0.056839	0.055155	0.063929					0.057363906
DES						0.055714	0.041941	
EDN1	-0.04828		-0.04554					
EOMES	0.084288	0.076171		0.045833				0.050475746
FABP4				-0.03939				
FBLN1	-0.07795	-0.06019	-0.0729	-0.04823			-0.06675	-0.099788911
FCGR2A		0.044455						
FCGR3B	0.040975	0.037913						0.072317848
FKBP11	0.063241	0.040355	0.056659					
FOLR2						-0.04681		
FOXI1	0.045565							
FOXN4						0.043416	0.043758	
FOXP3	0.039537		0.050424		0.048612		0.060758	0.056544832
FURIN							0.045908	
FUT4	0.08674	0.072236	0.040281	0.06246		0.044159		
GATA2						-0.04118		
GJA5	0.042105	0.043181						
GNLY	0.049135						0.039547	
GPR183							-0.05082	
GYPA		0.044047						
GZMK	0.162548	0.117448	0.066982	0.07485		0.102471	0.053519	0.121910499
HPGDS								-0.058750952
ICAM1							0.051938	
ICOSLG	0.094865	0.108561	0.059662	0.058779	0.06085	0.041286	0.046443	0.048873673
IDO1		0.039485				0.037285		
IFITM3								-0.0401819
IFNB1					0.064311			
IFNG		0.047643			-0.03724			0.04148565
IFNGR1	-0.06606	-0.06479	-0.04459		-0.06533	-0.0605		-0.043583766
IFNGR2		-0.04789						0.041613098
IGKC	0.200164	0.207234	0.10137	0.08933	0.115094	0.106026	0.061718	0.065923338
IGLL5					0.045037			
IL10RB			0.04243		0.042023	0.043005		
IL17A	0.051116	0.052451					0.049536	
IL1A	0.061588	0.050096						
IL1B		0.038184					0.038756	
IL22							0.041126	0.037526937
IL27	0.040339							
IL2RA	0.073001				0.053015		0.054686	

IL33									-0.03722
IL3RA									0.043497
IL4	0.03914								
IL5						0.065467		0.045197	
IL6									-0.053733035
IL6R								0.044341	
IL6ST	-0.05528								
IL7R		-0.04831				-0.05257			
INMT	-0.12332	-0.06816	-0.19792						-0.06262
ISG15	0.066814	0.038402	0.040259						
ITLN1	0.044288								0.049348458
JCHAIN	0.082298	0.052541			0.063171	0.058752			
KIT	-0.05272	-0.08017							-0.053323915
KLRC2					-0.04922			0.050395	
KLRD1								0.044409	
KRT13									0.041034312
KRT14	0.040772								
KRT15	0.046743								
LST1	0.176173	0.140293	0.075228	0.097155	0.048409	0.150042	0.066195	0.117086543	
LTF						0.058064			
MGP					0.060665				-0.047453011
MRC1					0.039171				
MSLN								-0.04002	-0.053807806
MUC5AC								-0.04623	
MUC5B	0.100919	0.037387	0.038258			0.037932			
MX1	0.037898								
NCAM1	0.129607	0.038924	0.070591	0.060254	0.040041				0.054425241
NRP1	-0.0381	-0.04668		-0.05298					
PAX5									0.053371989
PCSK1N									-0.076337283
PDCD1			0.037544						
PECAM1	-0.04893	-0.09513	-0.05137	-0.04777	-0.06127				
PLAC8	0.039513								
PLIN2		0.049445							
PPARG	0.037847								
PRF1								-0.04373	
PRG4	-0.06815	-0.04201	-0.07122	-0.06506					
PTN			-0.03789		-0.06056				
PTPRC									-0.05500837
RETN	0.066851	0.040041							
S100A8	0.048937								
SEMA3A					0.059976				
SFTA2	0.090868								
SFTPA1	-0.07088	-0.05154							
SFTPA2								-0.04342	

SFTPC	-0.18456	-0.09881	-0.07617	-0.07591	-0.05003	-0.06539	-0.06338	-0.11238912
SLC18A2	0.059352							0.053280437
TGFB1		-0.0503						0.042625481
TMPRSS2						-0.04518		-0.07145939
TPPP3								-0.038857276
TPSAB1		-0.04459	-0.04399			0.038693	-0.04669	-0.291267486
TYROBP				-0.04596				